Anti-il-11 antibodies

Abstract

Provided are antibodies bind to interleukin-11 (IL-11) and related compositions, useful for the treatment of a variety of diseases and conditions including cancers, inflammatory diseases, autoimmune diseases, and others.

Description

Docket No. LASS-009 / 01WO 338600-2154ANTI-IL-11 ANTIBODIESCROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Patent Application No. 63 / 728,021, filed on December 4, 2024, the contents of which are incorporated by reference herein in their entirety.STATEMENT REGARDING SEQUENCE LISTING

[0002] The Sequence Listing XML associated with this application is provided in XML file format and is hereby incorporated by reference into the specification. The name of the XML file containing the Sequence Listing XML is LASS_009_01WO_ST26.xml. The XML file is about 634,466 bytes, was created on December 4, 2025, and is being submitted electronically via USPTO Patent Center.BACKGROUND

[0003] Interleukin-11 (IL-11) is a pleiotropic cytokine that is part of the IL-6 family, and plays a prominent role in chronic inflammation, autoimmunity, cancer, pathological wound healing, aging and age-related disorders, and other diseases.

[0004] IL-11 binds to IL-11 receptor alpha (IL-1 IRa) with low affinity and then to gpl30, to form a high-affinity signaling complex. Via this signaling mechanism, IL-11 induces downstream phosphorylation of signal transducer and activator of transcription 3(STAT3) and extracellular signal-regulated kinase (ERK) pathways with subsequent effects on cellular proliferation, survival, migration / invasion, angiogenesis, and differentiation (Johnstone 2015). IL-11 production is stimulated by a number of fibroinflammatory mediators such as Interleukin- ip (IL- 1P), transforming growth factor-P (TGF-P), platelet-derived growth factor (PDGF), connective tissue growth factor (CTGF), and IL-13 (Ng 2020; Kortekaas 2021; Schafer 2017), and IL-11 itself has also been shown to be an important regulator of fibroblast activation across fibrotic diseases.

[0005] There is a need in the art for improved therapeutic approaches to treating inflammatory diseases, fibro-inflammatory diseases, autoimmune diseases, cancer, and other diseases involving IL-11 signaling pathways. Provided herein are compositions and methods that address these needs.SUMMARY

[0006] The present disclosure relates to antibodies that bind to IL- 11 and related compositions,Docket No. LASS-009 / 01WO 338600-2154 which may be used in any of a variety of therapeutic methods, including the treatment of cancer, an inflammatory disease, an autoimmune disease, a wasting disease, a bone disease, an age-related disease or disorder, or a fibro-inflammatory disease.

[0007] Aspects of the present disclosure include an antibody which binds to IL-11. In some embodiments, the present disclosure includes an antibody specific for IL-11, wherein the antibody blocks or interferes with IL-11 signaling, and wherein the antibody comprises a complementarity determining region (CDR) sequence combination selected from Table Bl or selected from Table CL In some embodiments, the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL) selected from Table C2. In some embodiments, the present disclosure includes an antibody which binds to IL-11, wherein the antibody comprises: a heavy chain variable region (VH) that comprises complementary determining region VHCDR1, VHCDR2, and VHCDR3 sequences selected from Table Al and variants thereof which specifically bind to IL- 11; and a light chain variable region (VL) that comprises complementary determining region VLCDR1, VLCDR2, and VLCDR3 sequences selected from Table Al, and variants thereof which specifically bind to IL-11. In some embodiments, variants which bind to IL-11 have 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 total alterations in any one or more of the individual CDRs, for example, any one or more the VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and / or VLCDR3 sequences of Table AL In some embodiments, the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to a sequence selected from Table A2. In some embodiments, the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to a sequence selected from Table A2.

[0008] In embodiments, the antibody is a monoclonal antibody. In embodiments, the antibody is an antibody fragment. In embodiments, the antibody is a human antibody. In embodiments, the antibody is a humanized antibody. In embodiments, the antibody is is a chimeric antibody. In embodiments, the antibody comprises an Fc domain. In embodiments, the Fc domain is IgA (including subclasses IgAl and IgA2), IgD, IgE, IgG (including subclasses IgGl, IgG2, IgG3, and IgG4), or IgM Fc domain, optionally a human Fc domain, or a hybrid and / or variant thereof.

[0009] Other aspects include a pharmaceutical composition, comprising an anti-IL-11 antibody described herein, and a pharmaceutically acceptable carrier. In some embodiments, the composition is a sterile, injectable solution, optionally suitable for intravenous, intramuscular, subcutaneous, or intraperitoneal administration.

[0010] Other aspects include a nucleic acid encoding an anti-IL-11 antibody described herein,Docket No. LASS-009 / 01WO 338600-2154 and a vector comprising said nucleic acid.

[0011] Further aspects included are methods of treating a disease or condition in a subject in need thereof, comprising administering to the subject a pharmaceutical composition described herein. In embodiments, the disease or condition is an IL- 11 -associated or IL- 11 -mediated disease or condition.

[0012] In some embodiments, the disease or condition is cancer. Exemplary cancers include, without limitation, bone cancer, prostate cancer, melanoma (e.g., metastatic melanoma), pancreatic cancer, small cell lung cancer, non-small cell lung cancer (NSCLC), mesothelioma, leukemia (e.g., lymphocytic leukemia, chronic myelogenous leukemia, acute myeloid leukemia, relapsed acute myeloid leukemia, hairy cell leukemias, acute lymphoblastic leukemias), lymphoma (e.g., non-Hodgkin’s lymphomas, Hodgkin’s lymphoma), hepatoma (hepatocellular carcinoma), sarcoma, B-cell malignancy, breast cancer, ovarian cancer, colorectal cancer, glioma, glioblastoma multiforme, meningioma, pituitary adenoma, vestibular schwannoma, primary CNS lymphoma, primitive neuroectodermal tumor (medulloblastoma), kidney cancer (e.g., renal cell carcinoma), bladder cancer, uterine cancer, esophageal cancer, brain cancer, head and neck cancers, cervical cancer, testicular cancer, thyroid cancer, and stomach cancer. In specific embodiments, the cancer is a metastatic cancer, for example, which has metastasized to the bone.

[0013] In some embodiments, the disease or condition is an inflammatory disease. Non-limiting examples of inflammatory diseases and conditions include airway or lung inflammation (e.g., inflammatory lung disease), asthma, rhinitis, chronic obstructive pulmonary disorder (COPD), dermatitis, psoriasis, hepatitis, gastric inflammation, irritable bowel syndrome (IBS), ulcerative colitis, Crohn’s disease, colitis, diverticulitis, lupus erythematous, nephritis, Parkinson’s disease, multiple sclerosis (MS), Alzheimer’s disease, arthritis, rheumatoid arthritis, sepsis, infection- induced inflammation, cardiovascular diseases such as atherosclerosis and vasculitis, diabetes, and gout.

[0014] In some embodiments, the disease or condition is an autoimmune disease. Non-limiting examples of autoimmune diseases and conditions include arthritis (including rheumatoid arthritis, reactive arthritis), systemic lupus erythematosus (SLE), psoriasis, inflammatory bowel disease (IBD), ulcerative colitis, Crohn’s disease, encephalomyelitis, uveitis, myasthenia gravis, multiple sclerosis, insulin dependent diabetes, Addison’s disease, celiac disease, chronic fatigue syndrome, autoimmune hepatitis, autoimmune alopecia, ankylosing spondylitis, fibromyalgia, pemphigus vulgaris, Sjogren’s syndrome, Kawasaki’s Disease, hyperthyroidism / Graves’ disease,Docket No. LASS-009 / 01WO 338600-2154 hypothyroidism / Hashimoto’s disease, endometriosis, scleroderma, pernicious anemia, Goodpasture syndrome, Guillain-Barre syndrome, Wegener’s disease, glomerulonephritis, aplastic anemia (including multiply transfused aplastic anemia patients), paroxysmal nocturnal hemoglobinuria, myelodysplastic syndrome, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, Evan’s syndrome, Factor VIII inhibitor syndrome, systemic vasculitis, dermatomyositis, polymyositis, rheumatic fever, autoimmune lymphoproliferative syndrome (ALPS), autoimmune bullous pemphigoid, Parkinson’s disease, sarcoidosis, vitiligo, primary biliary cirrhosis, and autoimmune myocarditis.

[0015] In some embodiments, the disease or condition is a wasting disease. Non-limiting examples of wasting diseases and conditions include cachexia, including cachexia associated with cancer or renal failure, and sarcopenia. In some embodiments, the disease or condition is a bone disease. Non-limiting examples of bone diseases and conditions include osteoporosis (including post-menopausal osteoporosis), bone fracture, Paget’s disease of bone, and bone resorption / damage associated with cancer or cancer therapy, including chemotherapy, hormone ablation, and hormone inhibition.

[0016] In some embodiments, the disease or condition is a fibro-inflammatory disease. Examples include fibrosis of the lungs, cardiovascular system, liver, brain, joints (e.g., knee, hip, ankle, foot joints, shoulder, elbow, wrist, hand joints, spinal vertebrae), intestine, skin, kidney, liver, thyroid, bone marrow, retroperitoneum, or eye (see, for example, Schafer et al., Nature. 552: 110-115, 2017; and Ng et al., Sci Transl Med. 2019 Sep 25;11(511)).

[0017] In some embodiments, the fibro-inflammatory disease is selected from fibrothorax, pulmonary fibrosis (for example, cystic fibrosis, interstitial lung disease (ILD), autosomal recessive genetic disease such as Hermansky-Pudlak syndrome type 1, 2, 3, 4, 5, 6, 7, or 8), and radiation-induced lung injury. In some embodiments, the pulmonary fibrosis is related to ILD, for example, idiopathic or secondary ILD. Examples of idiopathic ILD include idiopathic pulmonary fibrosis (IPF), desquamative interstitial pneumonia (DIP), acute interstitial pneumonia (AIP) also known as Hamman-Rich syndrome, nonspecific interstitial pneumonia (NSIP), respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), cryptogenic organizing pneumonia (COP), and lymphoid interstitial pneumonia (LIP). General examples of secondary ILD include ILD related to connective tissue and autoimmune diseases (for example, sarcoidosis, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, polymyositis, dermatomyositis, anti synthetase syndrome), inhaled substances (for example, silicosis, asbestosis, berylliosis,Docket No. LASS-009 / 01WO 338600-2154 industrial printing chemicals, chronic hypersensitivity pneumonitis), drugs (drug-induced ILD, for example, antibiotics, chemotherapeutics, anti -arrhythmic agents), infections (for example, SARS CoV-2, atypical pneumonia, pneumocystis pneumonia, tuberculosis, Chlamydia trachomatis, respiratory syncytial virus), malignancies (lymphangitic carcinomatosis), and pediatric ILDs such as diffuse developmental disorders, growth abnormalities deficient alveolarization, infant conditions of undefined cause, and ILD related to alveolar surfactant region.

[0018] In some embodiments, the fibro-inflammatory disease is myocardial fibrosis (for example, interstitial fibrosis, replacement fibrosis). In some embodiments, the fibro-inflammatory disease is thyroid eye disease (TED).

[0019] In some embodiments, the disease or condition is an age-related disease or disorder. In some embodiments, the age related disease or disorder is selected from the group consisting of cardiovascular disease (e.g., atherosclerosis, hypertension, heart failure, coronary artery disease), musculoskeletal disorders (e.g., osteoarthritis, osteoporosis, sarcopenia), neurodegenerative disease (e.g., Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s disease), metabolic disorders (e.g., type 2 diabetes mellitus, metabolic syndrome, dyslipidemia, non-alcoholic fatty liver disease (NAFLD)), ophthalmological disorders, (e.g., age- related macular degeneration (AMD), cataracts, glaucoma), pulmonary disorders (e.g., chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF)), hematologic disorders (e.g., anemia of aging, myelodysplastic syndromes), renal disorders (e.g., chronic kidney disease, age-related nephrosclerosis), immune disorders (e.g., immunosenescence, chronic inflammation), skin and connective tissue disorders (e.g., wrinkles, skin thinning, photoaging, age- related fibrosis), cancer (e.g. breast cancer, prostate cancer, colorectal cancer), and endocrine disorders (e.g., hypogonadism, age-related hormone decline). In some embodiments, the age- related disease or disorder is associated with elevated levels of IL-11.

[0020] Some aspects also relate to methods of treating, ameliorating the symptoms of, and / or slowing the progression of aging, age related diseases and disorders, cellular aging or senescence in a subject in need thereof. In some embodiments, the subject has elevated levels of IL-11.

[0021] In some embodiments, the antibodies of the disclosure are administered to a subject in order to extend or prolong the lifespan of a subject. In some embodiments, the antibodies of the disclosure are administered to a subject in order to slow, prevent, or reverse the development / presence of senescence and / or the senescent cells. In some embodiments, the antibodies of the disclosure reduce cellular senescence markers, alleviate chronic inflammationDocket No. LASS-009 / 01WO 338600-2154 associated with aging, and / or enhance overall tissue health.

[0022] In some aspects, administration may be achieved by a variety of different routes, including oral, parenteral, nasal, intravenous, ocular, intradermal, intramuscular, subcutaneous, installation into the bladder, transdermal, inhalation, sublingual, buccal, rectal, vaginal or topical. Preferred modes of administration depend upon the nature of the condition to be treated or prevented. Particular embodiments include administration by IV infusion.

[0023] In some aspects, the present disclosure provides a method of inhibiting one or more of hyaluronan production, IL-6 production, and MCP-1 production by a cell, comprising contacting the cell with an antibody disclosed herein or a pharmaceutical composition disclosed herein.

[0024] In some aspects, the present disclosure provides a method of inhibiting one or more of hyaluronan production, IL-6 production, and MCP-1 production in a subject, comprising administering to the subject a therapeutically effective amount of an antibody disclosed herein or a pharmaceutical composition disclosed herein.

[0025] In some aspects, the present disclosure provides a composition comprising an antibody disclosed herein or a pharmaceutical composition disclosed herein, for use in the treatment of a disease or condition. In embodiments, the disease or condition is a cancer, an inflammatory disease, an autoimmune disease, a wasting disease, a bone disease, an age-related disease or disorder, or a fibro-inflammatory disease.BRIEF DESCRIPTION OF THE DRAWINGS

[0026] FIGs. 1A-1B show concentration response curves of the IL-11 antibodies LA0053a, LA0054a and LA0060a in HEK293 STAT3-luciferase reporter assay using human IL-11 (FIG. 1A) and cynomolgus monkey IL-11 (FIG. IB).

[0027] FIG. 2 shows concentration response curves for the IL-11 antibodies LA0053a, LA0054a and LA0060a, demonstrating pSTAT3 inhibition in human dermal fibroblasts.

[0028] FIG. 3A-3B shows IL- 11 (FIG. 3A) and IL- 11R (FIG. 3B) mRNA expression by orbital fibroblasts from TED patients compared to healthy (non-TED) donor cells.

[0029] FIG. 4 shows the ability of LAS0054a to inhibit the production of hyaluronan (HA) in orbital fibroblasts from TED patients stimulated with 10 ng / mL IL-11.

[0030] FIG. 5A-5D show the ability of LAS0054a (1 pg) to inhibit proliferation (WST-1, FIG. 5A), HA production (FIG. 5B), IL-6 production (FIG. 5C), and MCP-1 production (FIG. 5D) in orbital fibroblasts from TED patients stimulated with a combination of IL- 11 at 10 ng / mL and IGF-1 at 100 ng / mL.Docket No. LASS-009 / 01WO 338600-2154

[0031] FIGs. 6A-6D show the ability of LAS0054a (1 pg) to inhibit proliferation (WST-1, FIG. 6A), HA production (FIG. 6B), IL-6 production (FIG. 6C), and MCP-1 production (FIG. 6D) in orbital fibroblasts from TED patients stimulated with a combination of IL- 11 at 10 ng / mL and IGF-1 at 100 ng / mL compared to a panel of IL-11 antibodies at equivalent concentrations.DETAILED DESCRIPTION

[0032] The present disclosure relates to novel antibodies that specifically bind IL-11 (herein referred to interchangeably as “IL-11 antibodies” or “anti-IL-11 antibodies” or “IL-11 specific antibodies”). In some embodiments, the IL-11 antibodies of the disclosure are capable of binding to IL-11, blocking IL-11 binding with its receptor IL-1 IRa, or blocking assembly of the signaling complex of IL- 11 / IL- 1 IRa with gpl30, and inhibiting downstream cell signaling and biological effects. In certain embodiments, an IL-1 IRa antibody of the disclosure is an IL-11 antagonist or inhibitor.

[0033] IL-11 antibodies described herein are useful in the treatment and prevention of various diseases and conditions associated with or mediated by IL-11 signaling, including but not limited to cancers, autoimmune diseases, and inflammatory diseases. In some embodiments, the IL-11 antibodies described herein are useful for treating conditions associated with aging or cellular senescence. Some embodiments thus relate to the use of IL-11 antibodies for the diagnosis, assessment, and treatment of diseases and conditions, including those associated with IL-11 activity or aberrant expression thereof.Definitions

[0034] Unless defined otherwise, all terms of art, notations, and other technical and scientific terms or terminology used herein are intended to have the same meaning as is commonly understood by one of ordinary skill in the art to which the claimed subject matter pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and / or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art.

[0035] As used in this specification and the appended claims, the singular forms “a,” “an” and “the” include plural references unless the content clearly dictates otherwise.

[0036] As used herein, the term “about” will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which it is used. In some embodiments, the term “about” when referring to a measurable value such as an amount, a temporal duration, and the like,Docket No. LASS-009 / 01WO 338600-2154 is meant to encompass art-accepted variations based on standard errors in making such measurements. In some embodiments, the term “about” when referring to such values, is meant to encompass variations of ±10% from the specified value.

[0037] As used herein, “affinity” refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). The affinity of a molecule for its partner can generally be represented by the equilibrium dissociation constant (KD) (or its inverse equilibrium association constant, KA). Affinity can be measured by common methods known in the art.

[0038] As used herein, the term “antibody” encompasses not only intact polyclonal or monoclonal antibodies, but also antigen binding fragments thereof (such as dAb, Fab, Fab’, F(ab’)2, Fv), single chain (scFv), synthetic variants thereof, naturally occurring variants, fusion proteins comprising an antibody portion with an antigen binding fragment of the required specificity, humanized antibodies, chimeric antibodies, and any other modified configuration of the immunoglobulin molecule that comprises an antigen binding site or fragment (epitope recognition site) of the required specificity. Certain features and characteristics of antibodies (and antigen binding fragments thereof) are described in greater detail herein.

[0039] As used herein, “antigen binding fragment” or “antibody fragment” refers to a portion of an immunoglobulin molecule that retains the heavy chain and the light chain antigen binding site, such as a heavy chain complementarity determining regions (VHCDR) 1 (VHCDR1), 2 (VHCDR2), and 3 (VHCDR3), a light chain complementarity determining regions (VLCDR) 1 (VLCDR1), 2 (VLCDR2), and 3 (VLCDR3), a heavy chain variable region (VH), or a light chain variable region (VL). Antibody fragments include, but are not limited to, a single-chain Fv (scFv) comprising VH and VL domains of an antibody wherein these domains are present in a single polypeptide chain, a Fab fragment (a monovalent fragment comprising a VL and a VH) and a F(ab) 2 fragment (a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region). VH and VL domains can be engineered and linked together via a synthetic linker to form various types of single chain antibody designs. Antibody fragments are obtained using well known techniques and the fragments are characterized in the same manner as are intact antibodies.

[0040] An antibody variable region comprises a framework region interrupted by the CDR antigen binding sites. The term “framework,” or “FR” or “framework sequence” refers to the remaining sequences of a variable region other than those sequences defined to be antigen bindingDocket No. LASS-009 / 01WO 338600-2154 sites. Because the antigen binding site can be defined by various terms as described above, the exact amino acid sequence of a framework depends on how the antigen-binding site is defined. FRs are located between CDRs, for example, with FR-H1 located before VHCDR1, FR-H2 located between VHCDR1 and VHCDR2, FR-H3 located between VHCDR2 and VHCDR3 and so forth.

[0041] The term “CDR” denotes a complementarity determining region as defined by at least one manner of identification to one of skill in the art. The precise amino acid sequence boundaries of a given CDR or FR can be readily determined using any of a number of well-known schemes, including those described by Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (“Kabat” numbering scheme); Al-Lazikani et al., (1997) JMB 273, 927-948 (“Chothia” numbering scheme); MacCallum et al., J. Mol. Biol. 262:732-745 (1996), “Antibody-antigen interactions: Contact analysis and binding site topography,” J. Mol. Biol. 262, 732-745.” (“Contact” numbering scheme); Lefranc M P et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Dev Comp Immunol, 2003 January; 27(l):55-77 (“IMGT” numbering scheme); Honegger A and Pluckthun A, “Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool,” J Mol Biol, 2001 Jun. 8; 309(3):657-70, (“Aho” numbering scheme); and Martin et al., “Modeling antibody hypervariable loops: a combined algorithm,” PNAS, 1989, 86(23):9268- 9272, (“AbM” numbering scheme).

[0042] The boundaries of a given CDR or FR may vary depending on the scheme used for identification. For example, the Kabat scheme is based on structural alignments, while the Chothia scheme is based on structural information.

[0043] In some embodiments, CDRs can be defined in accordance with any of the Chothia numbering schemes, the Kabat numbering scheme, the IMGT numbering scheme, a combination of Kabat, IMGT, and Chothia, the AbM definition, and / or the contact definition.

[0044] As used herein, the term “specifically binds” to a target molecule, such as an antigen, means that a binding molecule, such as a single domain antibody, reacts or associates more frequently, more rapidly, with greater duration, and / or with greater affinity with a particular target molecule than it does with alternative molecules. As such, “specific binding” does not necessarily require (although it can include) exclusive binding.

[0045] As used herein, percent (%)identity as it relates to amino acid sequences are defined asDocket No. LASS-009 / 01WO 338600-2154 the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in another peptide or polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity.. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or MEGALIGN (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.

[0046] The term “effective amount” as used herein means an amount of a pharmaceutical composition which is sufficient to significantly and positively modify the symptoms and / or conditions to be treated (e.g., provide a positive clinical response).

[0047] As used herein, the term “pharmaceutically acceptable” refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of a therapeutic compound, and is relatively nontoxic, i.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.

[0048] As used herein, the term “pharmaceutical composition” refers to a mixture of at least one targeted antibody of the disclosure with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and / or excipients. Multiple techniques of administering the antibodies and pharmaceutical compositions of the disclosure exist in the art including, but not limited to, intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary, and topical administration.

[0049] As used herein, the terms “treat,” “treating,” or “treatment” refer to ameliorating a disease or disorder, e.g., slowing or arresting or reducing the development of the disease or disorder or reducing at least one of the clinical symptoms thereof. For purposes of this disclosure, ameliorating a disease or disorder can include obtaining a beneficial or desired clinical result that includes, but is not limited to, any one or more of: alleviation of one or more symptoms, diminishment of extent of disease, preventing or delaying spread (for example, metastasis, for example metastasis to the lung or to the lymph node) of disease, preventing or delaying recurrence of disease, delay or slowing of disease progression, amelioration of the disease state, inhibiting the disease or progression of the disease, inhibiting or slowing the disease or its progression, arresting its development, and remission (whether partial or total).Docket No. LASS-009 / 01WO 338600-2154

[0050] The terms “individual” and “subject” are used interchangeably herein to refer to an animal; for example a mammal. The terms include human and veterinary animals. In some embodiments, methods of treating animals, including, but not limited to, humans, rodents, simians, felines, canines, equines, bovines, porcines, ovines, caprines, mammalian laboratory animals, mammalian farm animals, mammalian sport animals, and mammalian pets, are provided. The animal can be male or female and can be any suitable age, including infant, juvenile, adolescent, adult, and geriatric. In some examples, an “individual” or “subject” refers to an animal in need of treatment for a disease or disorder. In some embodiments, the animal to receive the treatment can be a “patient,” designating the fact that the animal has been identified as having a disorder of relevance to the treatment, or being at adequate risk of contracting the disorder. In particular embodiments, the animal is a human, such as a human patient.

[0051] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.IL-ll-Specific Antibodies

[0052] Provided herein are antibodies that bind to IL-11, and methods of treatment using such antibodies. The antibodies may be useful for treating IL-11 mediated diseases and disorders by blocking IL-11 signaling with its receptor IL-1 IRa.

[0053] The antibodies that bind to IL-11 may be interchangeably referred to herein as IL-11 antibodies, anti -IL- 11 antibodies, IL- 11 -directed antibodies and the like.

[0054] In some embodiments, the antibody binds human IL-11. In some embodiments, the antibody antagonizes (e.g., blocks or interferes with) the binding and / or signaling activity between IL-11 and IL- 1 IRa. In some embodiments, the IL-11 antibody prevents assembly of the IL-11 / IL- 11R signaling complex with gpl30. In some embodiments, the IL-11 antibody does not bind mouse IL- 11. In some embodiments, the IL- 11 antibody does not bind rat IL- 11. In some embodiments, the IL-11 antibody does not bind mouse or rat IL-11. In some embodiments, the IL- 11 antibody preferentially binds human IL- 11 over mouse IL- 11. In some embodiments, the IL- 11 antibody preferentially binds human IL-11 over rat IL-11.Exemplary IL-11 Antibodies

[0055] As noted above, the IL-11 antibodies of the disclosure bind to IL-11. In some embodiments, an IL-11 antibody of the disclosure modulates (e.g., interferes with, antagonizes,Docket No. LASS-009 / 01WO 338600-2154 inhibits) binding of IL-11 to its receptor, IL-l lRa. In other embodiments antibodies may inhibit assembly of the IL-11 signaling complex without blocking IL-1 IRa binding. An IL-11 antibody of the disclosure is characterized by or comprises a heavy chain variable region (VH) that comprises complementary determining region VHCDR1, VHCDR2, and VHCDR3 sequences, and a light chain variable region (VL) that comprises complementary determining region VLCDR1, VLCDR2, and VLCDR3 sequences. Exemplary VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 sequences for the identified clones are provided in Table Al and Table A2 below.Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154

[0056] Thus, in certain embodiments, an IL-11 antibody of the disclosure comprises a VHDocket No. LASS-009 / 01WO 338600-2154 sequence that comprises complementary determining region VHCDR1, VHCDR2, and VHCDR3 sequences selected from Table Al and variants thereof which bind to IL-11; and a VL sequence that comprises complementary determining region VLCDR1, VLCDR2, and VLCDR3 sequences selected from Table Al and variants thereof which bind to IL-11. In particular embodiments, an antibody comprises a VH sequence that comprises a VHCDR1, a VHCDR2, and a VHCDR3 sequence and a VL sequence that comprises a VLCDR1, a VLCDR2, and a VLCDR3 sequence, wherein all of the CDR sequences are from a single named antibody (e.g. LT400) in Table Al.

[0057] In certain embodiments, the CDR sequences of an IL- 11 antibody of the disclosure are as follows:

[0058] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 1, 2, 3, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 4, 5, 6, respectively;

[0059] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 7, 8, 9, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 10, 11, 12, respectively;

[0060] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 13, 14, 15, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 16, 17, 18, respectively;

[0061] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 19, 20, 21, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 22, 23, 24, respectively;

[0062] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 25, 26, 27, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 28, 29, 30, respectively;

[0063] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 31, 32, 33, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 34, 35, 36, respectively;

[0064] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 37, 38, 39, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 40, 41, 42, respectively;

[0065] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 43, 44, 45, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 46,Docket No. LASS-009 / 01WO 338600-215447, 48, respectively;

[0066] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 49, 50, 51, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 52, 53, 54, respectively;

[0067] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 55, 56, 57, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 58, 59, 60, respectively;

[0068] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 61, 62, 63, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 64, 65, 66, respectively;

[0069] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 67, 68, 69, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 70, 71, 72, respectively;

[0070] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 73, 74, 75, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 76, 77, 78, respectively;

[0071] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 79, 80, 81, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 82, 83, 84, respectively;

[0072] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 85, 86, 87, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 88, 89, 90, respectively;

[0073] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 91, 92, 93, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 94, 95, 96, respectively;

[0074] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 97, 98, 99, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 100, 101, 102, respectively;

[0075] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 103, 104,105, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:106, 107, 108, respectively;

[0076] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 109, 110,Docket No. LASS-009 / 01WO 338600-2154111, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:112, 113, 114, respectively;

[0077] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 115, 116,117, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:118, 119, 120, respectively;

[0078] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 121, 122,123, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:124, 125, 126, respectively;

[0079] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 127, 128,129, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:130, 131, 132, respectively;

[0080] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 133, 134,135, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:136, 137, 138, respectively;

[0081] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 139, 140,141, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:142, 143, 144, respectively;

[0082] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 145, 146,147, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:148, 149, 150, respectively;

[0083] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 151, 152,153, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:154, 155, 156, respectively;

[0084] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 157, 158,159, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:160, 161, 162, respectively;

[0085] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 163, 164,165, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:166, 167, 168, respectively;

[0086] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 169, 170,171, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:172, 173, 174, respectively;Docket No. LASS-009 / 01WO 338600-2154

[0087] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 175, 176,177, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:178, 179, 180, respectively;

[0088] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 181, 182,183, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:184, 185, 186, respectively;

[0089] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 187, 188,189, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:190, 191, 192, respectively;

[0090] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 193, 194,195, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:196, 197, 198, respectively;

[0091] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 199, 200,201, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:202, 203, 204, respectively;

[0092] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 205, 206,207, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:208, 209, 210, respectively;

[0093] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 211, 212,213, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:214, 215, 216, respectively;

[0094] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 217, 218,219, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:220, 221, 222, respectively;

[0095] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 223, 224,225, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:226, 227, 228, respectively;

[0096] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 229, 230,231, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:232, 233, 234, respectively;

[0097] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 235, 236, 237, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:Docket No. LASS-009 / 01WO 338600-2154238, 239, 240, respectively;

[0098] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 241, 242,243, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:244, 245, 246, respectively;

[0099] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 247, 248,249, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:250, 251, 252, respectively;[000100] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 253, 254,255, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:256, 257, 258, respectively;[000101] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 259, 260,261, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:262, 263, 264, respectively;[000102] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 265, 266,267, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:268, 269, 270, respectively;[000103] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 271, 272,273, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:274, 275, 276, respectively;[000104] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 277, 278,279, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:280, 281, 282, respectively;[000105] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 283, 284,285, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:286, 287, 288, respectively;[000106] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 289, 290,291, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:292, 293, 294, respectively;[000107] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 295, 296,297, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:298, 299, 300, respectively;[000108] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 301, 302,Docket No. LASS-009 / 01WO 338600-2154303, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:304, 305, 306, respectively;[000109] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 307, 308,309, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:310, 311, 312, respectively;[000110] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 313, 314,315, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:316, 317, 318, respectively;[000111] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 319, 320,321, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:322, 323, 324, respectively;[000112] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 325, 326,327, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:328, 329, 330, respectively;[000113] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 331, 332,333, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:334, 335, 336, respectively;[000114] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 337, 338,339, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:340, 341, 342, respectively;[000115] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 343, 344,345, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:346, 347, 348, respectively;[000116] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 349, 350,351, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:352, 353, 354, respectively;[000117] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 355, 356,357, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:358, 359, 360, respectively;[000118] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 361, 362,363, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:364, 365, 366, respectively;Docket No. LASS-009 / 01WO 338600-2154[000119] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 367, 368,369, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:370, 371, 372, respectively;[000120] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 373, 374,375, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:376, 377, 378, respectively;[000121] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 379, 380,381, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:382, 383, 384, respectively;[000122] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 385, 386,387, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:388, 389, 390, respectively;[000123] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 391, 392,393, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:394, 395, 396, respectively;[000124] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 397, 398,399, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:400, 401, 402, respectively;[000125] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 403, 404,405, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:406, 407, 408, respectively;[000126] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 409, 410,411, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:412, 413, 414, respectively;[000127]the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 415, 416,417, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:418, 419, 420, respectively;[000128] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 421, 422,423, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:424, 425, 426, respectively;[000129] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 427, 428, 429, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:DocketNo. LASS-009 / 01WO 338600-2154430, 431, 432, respectively;[000130] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 433, 434,435, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:436, 437, 438, respectively;[000131] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 439, 440,441, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:442, 443, 444, respectively;[000132] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 445, 446,447, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:448, 449, 450, respectively;[000133] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 451, 452,453, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:454, 455, 456, respectively;[000134] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 457, 458,459, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:460, 461, 462, respectively;[000135] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 463, 464,465, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:466, 467, 468, respectively;[000136] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 469, 470,471, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:472, 473, 474, respectively;[000137] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 475, 476,477, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:478, 479, 480, respectively;[000138]the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 481, 482,483, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:484, 485, 486, respectively; or[000139] the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 487, 488,489, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs:490, 491, 492, respectively.[000140] Also included are minor variants of the foregoing CDRs. Exemplary variants bind to IL-Docket No. LASS-009 / 01WO 338600-215411 and have 1, 2, 3, 4, or 5 total alterations in any one or more of the individual CDRs, for example, any one or more the VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and / or VLCDR3 sequences described herein. Exemplary “alterations” include amino acid substitutions, additions, and deletions. It is understood that these variants do not alter binding to IL-11.[000141] Exemplary VH and VL sequences, for the above-noted clones, are provided in Table A2 below (CDR sequences underlined).Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154[000142] Thus, in certain embodiments, an IL-11 antibody of the disclosure binds to IL-11 and comprises a VH sequence and a corresponding VL sequence selected from Table A2. In some embodiments, the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to a sequence selected from Table A2, including, for example, wherein the VH has 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 alterations in one or more framework regions and / or CDRs. In some embodiments, the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to a sequence selected from Table A2, including, for example, wherein the VL has 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 alterations in one or more framework regions and / or CDRs. In particular embodiments, the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to a sequence selected from Table A2 and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to a sequence selected from Table A2 and is from the same single named antibody (e.g. LT400) as the VH region. In particular embodiments, the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to a sequence selected from Table A2 and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to a sequence selected from Table A2 and is from the same single named antibody (e.g. LT400) as the VH region, wherein any alterations are not found in the CDRs as underlined in Table A2. Hence, an antibody may comprise VH and VL sequences that are at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to the respective sequences from a single named antibody (e.g. LT400) in Table A2, wherein the antibody comprises the CDRs of said single named antibody (e.g. LT400) as recited in Table Al.Docket No. LASS-009 / 01WO 338600-2154[000143] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 493, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 494. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 493, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 494.[000144] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 495, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 496. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 495, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 496.[000145] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 497, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 498. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 497, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 498.[000146] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 499, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 500. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 499, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 500.[000147] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 501, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 502. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 501, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 502.[000148] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 503, andDocket No. LASS-009 / 01WO 338600-2154 a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 504. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 503, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 504.[000149] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 505, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 506. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 505, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 506.[000150] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 507, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 508. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 507, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 508.[000151] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 509, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 510. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 509, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 510.[000152] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 511, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 512. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 511, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 512.[000153] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 513, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 514. In some embodiments, the VH of the IL-11 antibody comprises or consists of theDocket No. LASS-009 / 01WO 338600-2154 amino acid sequence of SEQ ID NO: 513, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 514.[000154] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 515, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 516. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 515, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 516.[000155] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 517, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 518. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 517, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 518.[000156] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 519, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 520. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 519, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 520.[000157] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 521, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 522. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 521, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 522.[000158] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 523, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 524. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 523, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 524.Docket No. LASS-009 / 01WO 338600-2154[000159] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 525, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 526. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 525, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 526.[000160] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 527, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 528. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 527, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 528.[000161] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 529, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 530. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 529, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 530.[000162] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 531, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 532. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 531, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 532.[000163] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 533, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 534. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 533, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 534.[000164] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 535, andDocket No. LASS-009 / 01WO 338600-2154 a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 536. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 535, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 536.[000165] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 537, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 538. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 537, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 538.[000166] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 539, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 540. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 539, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 540.[000167] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 541, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 542. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 541, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 542.[000168] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 543, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 544. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 543, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 544.[000169] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 545, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 546. In some embodiments, the VH of the IL-11 antibody comprises or consists of theDocket No. LASS-009 / 01WO 338600-2154 amino acid sequence of SEQ ID NO: 545, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 546.[000170] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 547, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 548. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 547, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 548.[000171] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 549, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 550. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 549, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 550.[000172] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 551, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 552. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 551, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 552.[000173] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 553, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 554. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 553, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 554.[000174] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 555, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 556. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 555, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 556.Docket No. LASS-009 / 01WO 338600-2154[000175] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 557, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 558. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 557, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 558.[000176] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 559, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 560. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 559, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 560.[000177] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 561, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 562. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 561, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 562.[000178] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 563, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 564. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 563, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 564.[000179] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 565, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 566. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 565, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 566.[000180] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 567, andDocket No. LASS-009 / 01WO 338600-2154 a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 568. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 567, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 568.[000181] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 569, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 570. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 569, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 570.[000182] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 571, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 572. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 571, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 572.[000183] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 573, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 574. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 573, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 574.[000184] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 575, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 576. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 575, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 576.[000185] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 577, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 578. In some embodiments, the VH of the IL-11 antibody comprises or consists of theDocket No. LASS-009 / 01WO 338600-2154 amino acid sequence of SEQ ID NO: 577, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 578.[000186] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 579, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 580. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 579, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 580.[000187] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 581, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 582. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 581, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 582.[000188] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 583, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 584. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 583, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 584.[000189] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 585, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 586. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 585, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 586.[000190] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 587, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 588. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 587, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 588.Docket No. LASS-009 / 01WO 338600-2154[000191] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 589, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 590. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 589, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 590.[000192] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 591, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 592. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 591, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 592.[000193] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 593, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 594. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 593, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 594.[000194] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 595, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 596. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 595, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 596.[000195] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 597, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 598. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 597, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 598.[000196] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 599, andDocket No. LASS-009 / 01WO 338600-2154 a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 600. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 599, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 600.[000197] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 601, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 602. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 601, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 602.[000198] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 603, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 604. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 603, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 604.[000199] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 605, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 606. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 605, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 606.[000200] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 607, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 608. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 607, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 608.[000201] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 609, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 610. In some embodiments, the VH of the IL-11 antibody comprises or consists of theDocket No. LASS-009 / 01WO 338600-2154 amino acid sequence of SEQ ID NO: 609, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 610.[000202] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 611, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 612. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: X611 and the VL of the IL-11 antibody comprises the amino acid sequence of SEQ ID NO: 612.[000203] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 613, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 614. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 613, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 614.[000204] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 615, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 616. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 615, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 616.[000205] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 617, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 618. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 617, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 618.[000206] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 619, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 620. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 619, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 620.Docket No. LASS-009 / 01WO 338600-2154[000207] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 621, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 622. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 621, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 622.[000208] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 623, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 624. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 623, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 624.[000209] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 625, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 626. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 625, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 626.[000210] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 627, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 628. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 627, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 628.[000211] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 629, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 630. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 629, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 630.[000212] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 631, andDocket No. LASS-009 / 01WO 338600-2154 a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 632. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 631, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 632.[000213] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 633, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 634. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 633, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 634.[000214] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 635, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 636. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 635, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 636.[000215] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 637, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 638. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 637, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 638.[000216] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 639, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 640. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 639, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 640.[000217] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 641, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 642. In some embodiments, the VH of the IL-11 antibody comprises or consists of theDocket No. LASS-009 / 01WO 338600-2154 amino acid sequence of SEQ ID NO: 641, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 642.[000218] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 643, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 644. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 643, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 644.[000219] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 645, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 646. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 645, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 646.[000220] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 647, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 648. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 647, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 648.[000221] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 649, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 650. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 649, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 650.[000222] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 651, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 652. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 651, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 652.Docket No. LASS-009 / 01WO 338600-2154[000223] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 653, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 654. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 653, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 654.[000224] In some embodiments, the IL-11 antibody of the disclosure comprises a VH comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 655, and a VL comprising a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 656. In some embodiments, the VH of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 655, and the VL of the IL-11 antibody comprises or consists of the amino acid sequence of SEQ ID NO: 656.[000225] Also included are variants thereof that bind to IL-11, for example, variants having 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 alterations in one or more framework regions of any one or more of the foregoing VH and / or VL sequences. Exemplary “alterations” include amino acid substitutions, additions, and deletions.[000226] In certain embodiments, an IL-11 antibody of the disclosure can be described using CDR consensus sequences. In some embodiments, the antibody comprises the VHCDR sequences of SEQ ID NOs: 657-659, and the VLCDR sequences of SEQ ID NOs: 660-662 (see Table Bl). In some embodiments, the antibody comprises the VHCDR sequences of SEQ ID NOs: 665-667, and the VLCDR sequences of SEQ ID NOs: 668-670 (see Table Cl). In certain embodiments, an antibody or antigen binding fragment thereof comprises the VH sequence of SEQ ID NO: 663, and the VL sequence of SEQ ID NO: 664 (see Table B2). In certain embodiments, an antibody or antigen binding fragment thereof comprises the VH sequence of SEQ ID NO: 671, and the VL sequence of SEQ ID NO: 672 (see Table C2).Docket No. LASS-009 / 01WO 338600-2154VLCDR3662DocketNo. LASS-009 / 01WO 338600-2154[000227] In embodiments, the antibody is a monoclonal antibody. In embodiments, the antibody is an antibody fragment. In embodiments, the antibody is a human antibody. In embodiments, the antibody is a humanized antibody. In embodiments, the antibody is a chimeric antibody. In embodiments, the antibody comprises an Fc domain. In embodiments, the Fc domain is IgA (including subclasses IgAl and IgA2), IgD, IgE, IgG (including subclasses IgGl, IgG2, IgG3, and IgG4), or IgM Fc domain, optionally a human Fc domain, or a hybrid and / or variant thereof.[000228] The disclosure also provides pharmaceutical compositions comprising any one of the IL-Docket No. LASS-009 / 01WO 338600-215411 antibodies disclosed herein, and optionally a pharmaceutical -acceptable excipient or carrier. In some embodiments, the pharmaceutical composition is sterile. The pharmaceutical compositions may be formulated to be compatible with their intended routes of administration. In some embodiments, the pharmaceutical compositions of the disclosure are suitable for administration to a human subject.[000229] In some embodiments, the IL-11 antibodies of the disclosure are encoded by a nucleic acid and are expressed, purified, and isolated. Accordingly, provided herein are nucleic acids encoding any of the antibodies disclosed herein, vectors comprising any of the nucleic acids encoding such antibodies, and host cells comprising such vectors. In some embodiments, the nucleic acid sequences encode for the VH and VL sequences of Table A2.[000230] In some embodiments, an IL-11 antibody of the disclosure binds to human IL-11 with a binding affinity of about 1 pM to about 10 pM to about 500 pM, or about, at least about, or less than about 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 300, 400, or 500 pM, or optionally with an affinity that ranges from about 1 pM to about 500 pM, about 1 pM to about 400 pM, about 1 pM to about 300 pM, about 1 pM to about 200 pM, about 1 pM to about 100 pM, about 1 pM to about 50 pM, about 1 pM to about 40 pM, about 1 pM to about 30 pM, about 1 pM to about 20 pM, about 1 pM to about 10 pM, about 1 pM to about 5 pM, about 5 pM to about 500 pM, about 5 pM to about 400 pM, about 5 pM to about 300 pM, about 5 pM to about 200 pM, about 5 pM to about 100 pM, about 5 pM to about 50 pM, about 5 pM to about 40 pM, about 5 pM to about 30 pM, about 5 pM to about 20 pM, about 5 pM to about 10 pM, about 10 pM to about 500 pM, about 10 pM to about 400 pM, about 10 pM to about 300 pM, about 10 pM to about 200 pM, about 10 pM to about 100 pM, about 10 pM to about 50 pM, about 10 pM to about 40 pM, about 10 pM to about 30 pM, about 10 pM to about 20 pM, or about 20 pM to about 500 pM, about 20 pM to about 400 pM, about 20 pM to about 300 pM, about 20 pM to about 200 pM, about 20 pM to about 100 pM, about 20 pM to about 50 pM, about 20 pM to about 40 pM, about 20 pM to about 30 pM, or about 30 pM to about 500 pM, about 30 pM to about 400 pM, about 30 pM to about 300 pM, about 30 pM to about 200 pM, about 30 pM to about 100 pM, about 30 pM to about 50 pM, or about 30 pM to about 40 pM.[000231] In some embodiments, an IL-11 antibody of the disclosure, is an IL-11 antagonist. In some instances, an IL-11 antibody of the disclosure, antagonizes the binding and / or signaling activity between IL-11 and its receptor, IL-11 Ra. In some embodiments, an IL-11 antibody of the disclosure, antagonizes or reduces the binding and / or signaling activity between IL- 11 and IL-Docket No. LASS-009 / 01WO 338600-2154HRa by about or at least about 10-1000% (e.g., about 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000% or more), for example, in a cellbased assay. In some embodiments, an IL-11 antibody of the disclosure reduces IL- 11 -mediated STAT3 phosphorylation. In an exemplary assay, cells expressing IL-1 IRa and gpl30 are cultured in the presence of IL-11 in the presence or absence of an IL-11 antibody of the disclosure. The level of STAT3 phosphorylation is then assessed by Western blotting or FACS using an antibody specific for phosphorylated STAT3. An exemplary assay making use of FACS is described in Dams-Kozlowska et al., BMC Biotechnol, 12: 8, 2012. In certain embodiments, an IL-11 antibody of the disclosure has no detectable agonist activity with respect to IL-11 signaling.[000232] In some embodiments, an IL-11 antibody of the disclosure inhibits or otherwise reduces IL-1 IRa dimerization or complex formation, for example, with gpl30. In certain embodiments, an IL-11 antibody of the disclosure inhibits or otherwise reduces IL- 1 IRa dimerization or complex formation by about or at least about 10-1000% (e.g., about 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000% or more), for example, in a cell-based assay.[000233] In some embodiments, an IL-11 antibody of the disclosure reduces proliferation of cells (e.g., BaF3 cells, B9 cells, T10 cells) expressing IL-1 IRa and gpl30 (e.g., cells naturally- expressing or modified to express both proteins) which are cultured in the presence of IL-11. Methods for assessing cell proliferation are known in the art and include, for example, MTT reduction and / or thymidine incorporation. Assays with B9 cells or T10 cells are described (see Dams-Kozlowska et al., BMC Biotechnol, 12: 8, 2012; and Yokote et al., J AO AC, 83: 1053- 1057, 2000). For T10 cells, proliferation can be measured by colorimetrically detecting reduction of the tetrazolium compound, 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-l,3- benzene disulfonate (WST-1). An IL-l l-binding protein that reduces the level of proliferation compared to the level observed in the absence of the IL-11-binding protein is considered to reduce or otherwise reduce IL-11 signaling.[000234] Merely for illustrative purposes, the binding interactions between IL-11 and an IL-11 antibody of the disclosure, or the binding / signaling between IL-1 IRa and IL-11, can be detected and quantified using a variety of routine methods, including Biacore® assays (for example, with appropriately tagged soluble reagents, bound to a sensor chip), FACS analyses with cells expressing IL- 1 IRa on the cell surface (either native, or recombinant), immunoassays, fluorescence staining assays, ELISA assays, and microcalorimetry approaches such as ITCDocket No. LASS-009 / 01WO 338600-2154(Isothermal Titration Calorimetry). Similarly, the functional properties of anti -IL- 11 antibodies may be assessed using a variety of methods known to the skilled person affinity / binding assays (for example, surface plasmon resonance, competitive inhibition assays); cytotoxicity assays, cell viability assays, cell proliferation or differentiation assays, among others. Other assays may test the ability of antibodies described herein to block normal IL- 11 -mediated responses. The antibodies described herein may also be tested for in vitro and in vivo efficacy. Such assays may be performed using well-established protocols known to the skilled person (see e.g., Current Protocols in Molecular Biology (Greene Publ. Assoc. Inc. & John Wiley & Sons, Inc., NY, NY); Current Protocols in Immunology (Edited by: John E. Coligan, Ada M. Kruisbeek, David H. Margulies, Ethan M. Shevach, Warren Strober 2001 John Wiley & Sons, NY, NY); or commercially available kits.[000235] In some embodiments, the IL-11 antibodies of the disclosure contain an Fc domain. In some embodiments, the Fc domain (interchangeably referred to as a Fc sequence, Fc region, or simply Fc) of the IL-11 antibodies is a human Fc domain. In some embodiments, the Fc domain of the IL-11 antibodies is human IgGl, human IgG2, human IgG3, or human IgG4.[000236] In particular embodiments, the heavy chain constant region or Fc region of an antibody, or antigen binding fragment thereof, comprises, consists, or consists essentially an IgA (including subclasses IgAl and IgA2), IgD, IgE, IgG (including subclasses IgGl, IgG2, IgG3, and IgG4), or IgM heavy chain constant region or Fc domain, optionally a human Fc domain, or a hybrid and / or variant thereof. In particular embodiments, the heavy chain constant region or Fc region comprises, consists, or consists essentially of the heavy chain constant region or Fc region from human IgGl or IgG4 (see, e.g., Allberse and Schuurman, Immunology. 105:9-19, 2002), or a fragment or variant thereof. Table Fl below provides exemplary heavy chain constant region sequences (CHI, hinge (underlined), CH2, and CH3 regions) from human IgG4. Examples of variant IgG4 sequences that can be employed include the S228P / S241P variant.Docket No. LASS-009 / 01WO 338600-2154[000237] In certain embodiments, an IL-11 antibody of the disclosure comprises variant or otherwise modified Fc region(s), including those having altered properties or biological activities relative to wild-type Fc region(s). Examples of modified Fc regions include those having mutated sequences, for instance, by substitution, insertion, deletion, or truncation of one or more amino acids relative to a wild-type sequence, hybrid Fc polypeptides composed of domains from different immunoglobulin classes / subclasses, Fc polypeptides having altered glycosylation / sialylation patterns, and Fc polypeptides that are modified or derivatized, for example, by biotinylation (see, e.g., US Application No. 2010 / 0209424), phosphorylation, sulfation, etc., or any combination of the foregoing. Such modifications can be employed to alter (e.g., increase, decrease) the binding properties of the Fc region to one or more particular FcRs (e.g., FcyRI, FcyRIIa, FcyRIIb, FcyRIIc, FcyRIIIa, FcyRIIIb, FcRn), its pharmacokinetic properties (e.g., stability or half-life, bioavailability, tissue distribution, volume of distribution, concentration, elimination rate constant, elimination rate, area under the curve (AUC), clearance, Cmax, tmax, Cmin, fluctuation), its immunogenicity, its complement fixation or activation, and / or the CDC / ADCC / ADCP-related activities of the Fc region, among other properties described herein, relative to a correspondingDocket No. LASS-009 / 01WO 338600-2154 wild-type Fc sequence of an antibody or antigen binding fragment thereof. Included are modified Fc regions of human and / or mouse origin.[000238] In some embodiments, the Fc domain of the IL-11 antibodies of the disclosure is a human IgGl Fc sequence. An exemplary, but non-limiting, sequence of heavy chain constant regions of human IgGl encompassing Fc domains of interest are provided as SEQ ID NO: 675.[000239] In some embodiments, the Fc domain of an IL-11 antibody of the disclosure is from a human IgGl constant heavy chain (e.g. SEQ ID NO: 675) and may comprise one or more Fc amino acid substitutions. In some embodiments, the Fc amino acid substitutions increase the halflife of the IL-11 antibody. In some embodiments, the Fc amino acid substitutions are M252Y, S254T, and T256E wherein the position numbers of the amino acid residues are of the EU numbering scheme. In some embodiments, the Fc amino acid substitutions are M428L and N434S wherein the position numbers of the amino acid residues are of the EU numbering scheme.[000240] The EU numbering scheme is one of many available antibody numbering schemes based on the residue numbers assigned to a canonical antibody sequence. Accordingly, a skilled artisan would understand that reference to a particular residue using the EU numbering scheme may or may not be exactly the residue in one of the IL-11 antibodies of the disclosure. For example, if an IL-11 antibody of the disclosure comprises a M428L substitution in the Fc, wherein the position number of the amino acid residue is of the EU numbering scheme, the residue may not be the actual residue 428 in that particular IL-11 antibody. It may be actual residue number 427, or 428, or 429, or others. Accordingly, a skilled artisan will understand how to correspond the recited residue using the EU numbering scheme, to the actual residue in an IL- 11 antibody of the disclosure. The EU numbering system for antibodies is known in the art and is described, for example, at imgt.org / IMGTScientificChart / Numbering / Hu_IGHGnber.html.[000241] In some embodiments, the Fc domain of the IL-11 antibodies of the disclosure is a human IgG4 Fc sequence. An exemplary, but non-limiting, sequence of heavy chain constant region of human IgG4 encompassing Fc domain of interest is provided as SEQ ID NO: 673. SEQ ID NO: 673 provides the canonical human IgG4 heavy chain constant region sequence. SEQ ID NO: 674 provides the canonical human IgG4 heavy chain constant region sequence with an S228P substitution wherein the position numbers of the amino acid residues are of the EU numbering scheme.[000242] In some embodiments, the Fc domain of an IL-11 antibody of the disclosure is from a human IgG4 constant heavy chain (e.g. SEQ ID NO: 673) and may comprise one or more FcDocket No. LASS-009 / 01WO 338600-2154 amino acid substitutions. An exemplary, but non-limiting, sequence of heavy chain constant region of human IgG4 encompassing Fc domain of interest with an Fc amino acid substitution is provided as SEQ ID NO: 674. In some embodiments, the Fc amino acid substitutions increase the half-life of the IL-11 antibody. In some embodiments, the Fc amino acid substitutions to SEQ ID NO: 673 are M252Y, S254T, and T256E wherein the position numbers of the amino acid residues are of the EU numbering scheme. In some embodiments, the Fc amino acid substitutions are M428L and N434S wherein the position numbers of the amino acid residues are of the EU numbering scheme.[000243] In certain embodiments, an antibody or antigen binding fragment thereof comprises a hybrid Fc region, for example, an Fc region that comprises a combination of Fc domains (e.g., hinge, CH2, CH3, CH4) from immunoglobulins of different species (e.g., human, mouse), different Ig classes, and / or different Ig subclasses. Also included are antibodies or antigen binding fragments thereof that comprise derivatized or otherwise modified Fc regions. In certain aspects, the Fc region is modified by phosphorylation, sulfation, acrylation, glycosylation, methylation, farnesylation, acetylation, amidation, and the like, for instance, relative to a wild-type or naturally- occurring Fc region. In certain embodiments, the Fc region comprises wild-type or native glycosylation patterns, or alternatively, it comprises increased glycosylation relative to a native form, decreased glycosylation relative to a native form, or it is entirely deglycosylated. As one example of a modified Fc glycoform, decreased glycosylation of an Fc region reduces binding to the Clq region of the first complement component Cl, a decrease in ADCC-related activity, and / or a decrease in CDC-related activity. Certain embodiments thus employ a deglycosylated or aglycosylated Fc region. See, e.g., WO 2005 / 047337 for the production of exemplary aglycosylated Fc regions. Another example of an Fc region glycoform is generated by substituting the Q295 position with a cysteine residue (see, e.g., U.S. Application No. 2010 / 0080794), according to the Kabat et al. numbering system. Certain embodiments include Fc regions where about 80-100% of the glycoprotein in Fc region comprises a mature core carbohydrate structure that lacks fucose (see, e.g., U.S. Application No. 2010 / 0255013). Some embodiments include Fc regions that are optimized by substitution or deletion to reduce the level of fucosylation, for instance, to increase affinity for FcyRI, FcyRIa, or FcyRIIIa, and / or to improve phagocytosis by FcyRIIa-expressing cells (see U.S. Application Nos. 2010 / 0249382 and 2007 / 0148170).[000244] As another example of a modified Fc glycoform, an Fc region of an IL-11 antibody of the disclosure may comprise oligomannose-type N-glycans, and optionally have one or more ofDocket No. LASS-009 / 01WO 338600-2154 the following: increased ADCC effector activity, increased binding affinity for FcyRIIIA (and certain other FcRs), similar or increased binding specificity for the target of the IL-11 polypeptide, similar or higher binding affinity for the target of the IL-11 polypeptide, and / or similar or lower binding affinity for mannose receptor, relative to a corresponding Fc region that contains complextype N-glycans (see, e.g., U.S. Application No. 2007 / 0092521 and U.S. PatentNo. 7,700,321). As another example, enhanced affinity of Fc regions for FcyRs has been achieved using engineered glycoforms generated by expression of antibodies in engineered or variant cell lines (see, e.g., Umana et al., Nat Biotechnol. 17: 176-180, 1999; Davies et al., Biotechnol Bioeng. 74:288-294, 2001; Shields et al., J Biol Chem. 277:26733-26740, 2002; Shinkawa et al., 2003, J Biol Chem. 278:3466-3473, 2003; and U.S. Application No. 2007 / 0111281). Certain Fc region glycoforms comprise an increased proportion of N-gly coside bond type complex sugar chains, which do not have the 1 -position of fucose bound to the 6-position of N-acetylglucosamine at the reducing end of the sugar chain (see, e.g., U.S. Application No. 2010 / 0092997). Particular embodiments may include IgG Fc region that is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by an a-2,6 linkage, optionally where the Fc region has a higher anti-inflammatory activity relative to a corresponding, wild-type Fc region (see U.S. Application No. 2008 / 0206246). Certain of these and related altered glycosylation approaches have generated substantial enhancements of the capacity of Fc regions to selectively bind FcRs such as FcyRIII, to mediate ADCC, and to alter other properties of Fc regions, as described herein. [000245] Certain variant, fragment, hybrid, or otherwise modified Fc regions of an antibody or antigen binding fragment thereof may have altered binding to one or more FcRs, and / or corresponding changes to effector function, relative to a corresponding, wild-type Fc sequence (e.g., same species, same Ig class, same Ig subclass). For instance, such Fc regions may have increased binding to one or more of Fey receptors, Fea receptors, Fes receptors, and / or the neonatal Fc receptor, relative to a corresponding, wild-type Fc sequence. In other embodiments, variant, fragment, hybrid, or modified Fc regions may have decreased binding to one or more of Fey receptors, Fea receptors, Fes receptors, and / or the neonatal Fc receptor, relative to a corresponding, wild-type Fc sequence. Specific FcRs are described elsewhere herein.[000246] In some embodiments, an IL-11 antibody of the disclosure comprises an Fc domain, comprising one or more mutations to increase binding to one or more of Fey receptors, Fea receptors, Fes receptors, and / or the neonatal Fc receptor, relative to a corresponding, wild-type Fc sequence. In some embodiments, an IL-11 antibody of the disclosure comprises an IgGl or IgG3Docket No. LASS-009 / 01WO 338600-2154Fc domain, comprising one or more mutations to increase binding to one or more of Fey receptors, Fea receptors, Fes receptors, and / or the neonatal Fc receptor, relative to a corresponding, wildtype Fc sequence. In some embodiments, an IL-11 antibody of the disclosure comprises an Fc domain, comprising one or more mutations to increase effector function. In some embodiments, an IL-11 antibody of the disclosure comprises an Fc domain selected from a human IgGl and IgG3, optionally comprising one or more mutations to increase effector function.[000247] In some embodiments, an IL-11 antibody of the disclosure comprises an Fc domain, comprising one or more mutations to decrease binding to one or more of Fey receptors, Fea receptors, Fes receptors, and / or the neonatal Fc receptor, relative to a corresponding, wild-type Fc sequence. In some embodiments, an IL-11 antibody of the disclosure comprises an IgGl or IgG3 Fc domain, comprising one or more mutations to decrease binding to one or more of Fey receptors, Fea receptors, Fes receptors, and / or the neonatal Fc receptor, relative to a corresponding, wildtype Fc sequence. In some embodiments, an IL-11 antibody of the disclosure comprises an Fc domain, comprising one or more mutations to decrease effector function. In some embodiments, an IL- 11 antibody of the disclosure comprises an Fc domain selected from a human IgG2 and IgG4, comprising one or more mutations to decrease effector function.[000248] Specific examples of Fc variants having altered (e.g., increased, decreased) effector function / FcR binding can be found, for example, in U.S. Pat. Nos. 5,624,821 and 7,425,619; U.S. Application Nos. 2009 / 0017023, 2009 / 0010921, and 2010 / 0203046; and WO 2000 / 42072 and WO 2004 / 016750. Certain examples include human Fc regions having a one or more substitutions at position 298, 333, and / or 334, for example, S298A, E333A, and / or K334A (based on the numbering of the EU index of Kabat et al.), which have been shown to increase binding to the activating receptor FcyRIIIa and reduce binding to the inhibitory receptor FcyRIIb. These mutations can be combined to obtain double and triple mutation variants that have further improvements in binding to FcRs. Certain embodiments include a S298A / E333A / K334A triple mutant, which has increased binding to FcyRIIIa, decreased binding to FcyRIIb, and increased ADCC (see, e.g., Shields et al., J Biol Chem. 276:6591-6604, 2001; and Presta et al., Biochem Soc Trans. 30:487-490, 2002). See also engineered Fc glycoforms that have increased binding to FcRs, as disclosed in Umana et al., supra; and U.S. Patent No. 7,662,925. Some embodiments include Fc regions that comprise one or more substitutions selected from 434S, 252Y / 428L, 252Y / 434S, and 428L / 434S (see U.S. Application Nos. 2009 / 0163699 and 20060173170), based on the EU index of Kabat et al.Docket No. LASS-009 / 01WO 338600-2154[000249] Certain variant, fragment, hybrid, or modified Fc regions may have altered effector functions, relative to a corresponding, wild-type Fc sequence. For example, such Fc regions may have increased complement fixation or activation, increased Clq binding affinity, increased CDC- related activity, increased ADCC-related activity, and / or increased ADCP-related activity, relative to a corresponding, wild-type Fc sequence. In other embodiments, such Fc regions may have decreased complement fixation or activation, decreased Clq binding affinity, decreased CDC- related activity, decreased ADCC-related activity, and / or decreased ADCP-related activity, relative to a corresponding, wild-type Fc sequence. As merely one illustrative example, an Fc region may comprise a deletion or substitution in a complement-binding site, such as a Clq- binding site, and / or a deletion or substitution in an ADCC site. Examples of such deletions / substitutions are described, for example, in U.S. Patent No. 7,030,226. Many Fc effector functions, such as ADCC, can be assayed according to routine techniques in the art. (see, e.g., Zuckerman et al., CRC Crit Rev Microbiol. 7: 1-26, 1978). Useful effector cells for such assays includes, but are not limited to, natural killer (NK) cells, macrophages, and other peripheral blood mononuclear cells (PBMC). Alternatively, or additionally, certain Fc effector functions may be assessed in vivo, for example, by employing an animal model described in Clynes et al. PNAS. 95:652-656, 1998.[000250] Certain variant hybrid, or modified Fc regions may have altered stability or half-life relative to a corresponding, wild-type Fc sequence. In certain embodiments, such Fc regions may have increased half-life relative to a corresponding, wild-type Fc sequence. In other embodiments, variant hybrid, or modified Fc regions may have decreased half-life relative to a corresponding, wild-type Fc sequence. Half-life can be measured in vitro (e.g., under physiological conditions) or in vivo, according to routine techniques in the art, such as radiolabeling, ELISA, or other methods. In vivo measurements of stability or half-life can be measured in one or more bodily fluids, including blood, serum, plasma, urine, or cerebrospinal fluid, or a given tissue, such as the liver, kidneys, muscle, central nervous system tissues, bone, etc. As one example, modifications to an Fc region that alter its ability to bind the FcRn can alter its half-life in vivo. Assays for measuring the in vivo pharmacokinetic properties (e.g., in vivo mean elimination half-life) and non-limiting examples of Fc modifications that alter its binding to the FcRn are described, for example, in U.S. Pat. Nos. 7,217,797 and 7,732,570; and U.S. Application Nos. US 2010 / 0143254 and 2010 / 0143254.[000251] Additional non-limiting examples of modifications to alter stability or half-life includeDocket No. LASS-009 / 01WO 338600-2154 substitutions / deletions at one or more of amino acid residues selected from 251-256, 285-290, and 308-314 in the CH2 domain, and 385-389 and 428-436 in the CH3 domain, according to the numbering system of Kabat et al. See U.S. Application No. 2003 / 0190311. Specific examples include substitution with leucine at position 251, substitution with tyrosine, tryptophan or phenylalanine at position 252, substitution with threonine or serine at position 254, substitution with arginine at position 255, substitution with glutamine, arginine, serine, threonine, or glutamate at position 256, substitution with threonine at position 308, substitution with proline at position 309, substitution with serine at position 311, substitution with aspartate at position 312, substitution with leucine at position 314, substitution with arginine, aspartate or serine at position 385, substitution with threonine or proline at position 386, substitution with arginine or proline at position 387, substitution with proline, asparagine or serine at position 389, substitution with methionine or threonine at position 428, substitution with tyrosine or phenylalanine at position 434, substitution with histidine, arginine, lysine or serine at position 433, and / or substitution with histidine, tyrosine, arginine or threonine at position 436, including any combination thereof. Such modifications optionally increase affinity of the Fc region for the FcRn and thereby increase halflife, relative to a corresponding, wild-type Fc region.[000252] Certain variant hybrid, or modified Fc regions may have altered solubility relative to a corresponding, wild-type Fc sequence. In certain embodiments, such Fc regions may have increased solubility relative to a corresponding, wild-type Fc sequence. In other embodiments, variant hybrid, or modified Fc regions may have decreased solubility relative to a corresponding, wild-type Fc sequence. Solubility can be measured, for example, in vitro (e.g., under physiological conditions) according to routine techniques in the art.[000253] Variant Fc regions can also have one or more mutated hinge regions, as described, for example, in U.S. Application No. 2003 / 0118592. For instance, one or more cysteines in a hinge region can be deleted or substituted with a different amino acid. The mutated hinge region can comprise no cysteine residues, or it can comprise 1, 2, or 3 fewer cysteine residues than a corresponding, wild-type hinge region. In some embodiments, an Fc region having a mutated hinge region of this type exhibits a reduced ability to dimerize, relative to a wild-type Ig hinge region.[000254] In some embodiments, the IL- 11 antibodies of the disclosure contain a light chain constant domain. In some embodiments, the light chain constant domain of the IL-11 antibodies is a human K (kappa) or human 1 (lambda) constant domain sequence. An exemplary, but nonDocket No. LASS-009 / 01WO 338600-2154 limiting, sequence of a human K (kappa) constant domain sequence is provided as SEQ ID NO: 676.RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 676)Bispecific antibodies[000255] The disclosure also provides bispecific antibodies which target IL-11 and a second target antigen. The bispecific antibody of the disclosure may be generated by any known method in the art. In some embodiments, the bispecific antibody comprises a first antigen binding arm that specifically binds IL-11 and a second antigen binding arm that specifically binds to a disease- associated antigen. In some embodiments, the bispecific antibody comprises a first antigen binding arm that specifically binds IL- 11 and a second antigen binding arm that specifically binds to a TED-associated antigen. In some embodiments, the first antigen binding arm is derived from any one of the IL-11 antibodies of the disclosure.[000256] In some embodiments, the first antigen binding arm that specifically binds to IL-11, comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: [000257] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 493, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 494;[000258] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 495, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 496;[000259] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 497, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 498;[000260] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 499, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 500;[000261] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 501, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 502;[000262] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identicalDocket No. LASS-009 / 01WO 338600-2154 to SEQ ID NO: 503, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 504;[000263] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 505, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 506;[000264] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 507, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 508;[000265] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 509, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 510;[000266] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 511, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 512;[000267] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 513, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 514;[000268] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 515, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 516;[000269] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 517, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 518;[000270] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 519, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 520;[000271] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 521, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 522;[000272] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 523, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 524;Docket No. LASS-009 / 01WO 338600-2154[000273] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 525, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 526;[000274] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 527, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 528;[000275] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 529, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 530;[000276] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 531, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 532;[000277] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 533, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 534;[000278] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 535, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 536;[000279] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 537, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 538;[000280] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 539, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 540;[000281] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 541, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 542;[000282] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 543, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 544;[000283] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 545, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99,Docket No. LASS-009 / 01WO 338600-2154 or 100% identical to SEQ ID NO: 546;[000284] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 547, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 548;[000285] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 549, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 550;[000286] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 551, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 552;[000287] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 553, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 554;[000288] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 555, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 556;[000289] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 557, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 558;[000290] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 559, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 560;[000291] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 561, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 562;[000292] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 563, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 564;[000293] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 565, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 566;[000294] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identicalDocket No. LASS-009 / 01WO 338600-2154 to SEQ ID NO: 567, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 568;[000295] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 569, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 570;[000296] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 571, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 572;[000297] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 573, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 574;[000298] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 575, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 576;[000299] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 577, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 578;[000300] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 579, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 580;[000301] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 581, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 582;[000302] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 583, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 584;[000303] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 585, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 586;[000304] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 587, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 588;Docket No. LASS-009 / 01WO 338600-2154[000305] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 589, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 590;[000306] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 591, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 592;[000307] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 593, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 594;[000308] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 595, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 596;[000309] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 597, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 598;[000310] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 599, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 600;[000311] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 601, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 602;[000312] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 603, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 604;[000313] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 605, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 606;[000314] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 607, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 608;[000315] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 609, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99,Docket No. LASS-009 / 01WO 338600-2154 or 100% identical to SEQ ID NO: 610;[000316] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 611, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 612;[000317] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 613, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 614;[000318] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 615, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 616;[000319] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 617, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 618;[000320] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 619, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 620;[000321] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 621, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 622;[000322] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 623, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 624;[000323] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 625, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 626;[000324] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 627, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 628;[000325] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 629, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 630;[000326] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identicalDocket No. LASS-009 / 01WO 338600-2154 to SEQ ID NO: 631, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 632;[000327] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 633, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 634;[000328] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 635, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 636;[000329] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 637, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 638;[000330] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 639, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 640;[000331] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 641, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 642;[000332] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 643, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 644;[000333] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 645, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 646;[000334] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 647, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 648;[000335] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 649, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 650;[000336] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 651, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 652;Docket No. LASS-009 / 01WO 338600-2154[000337] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 653, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 654; or[000338] the VH comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 655, and the VL comprises a sequence at least 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100% identical to SEQ ID NO: 656.[000339] In some embodiments, the second antigen binding arm that specifically binds to a TED associated antigen selected from the group consisting of insulin-like growth factor-1 receptor (IGF-1R), IGF-1, FcRn, interleukin-6 (IL-6), IL-6R, CD20, tumor necrosis factor-a (TNF-a), TNFR1, TNFR2, interleukin- 17 (IL- 17), IL-17R, CD-40, and CD-40L. In some embodiments, the second antigen binding arm comprises a VH and a VL sequence that binds insulin-like growth factor-1 receptor (IGF-1R), IGF-1, FcRn, interleukin-6 (IL-6), IL-6R, CD20, tumor necrosis factor-a (TNF-a), TNFR1, TNFR2, interleukin- 17 (IL-17), IL-17R, CD-40, or CD-40L.In some embodiments, the second antigen binding arm comprises a VH and a VL sequence derived from an antibody selected from the group consisting of teprotumumab, VRDN-001, VRDN-003, Lonigutamab, batoclimab (IMVT-1401), IMVT-1402, efgartigimod, nipocalimab, orilanolimab, rozanolixizumab, TOUR006, satralizumab clazakizumab, elsilimomab, levilimab, olokizumab, sarilumab, siltuximab, sirukumab, tocilizumab, ibritumomab, obinutuzumab, ocrelizumab, ofatumumab, rituximab, ublituximab, adalimumab, certolizumab, golimumab, and infliximab.Methods of use[000340] Certain embodiments relate to methods of treating, ameliorating the symptoms of, and / or reducing the progression of, a disease or condition in a subject in need thereof, comprising administering to the subject an antibody that binds to IL-11, as described herein, or a pharmaceutical composition comprising the same. In some instances, the antibody or antigen binding fragment thereof antagonizes the binding / signaling activity between the IL-11 and its receptor, IL-l lRa. In some embodiments, the disease or condition is an IL- 11 -associated or IL- 11-mediated disease or condition. In some embodiments, the disease or condition is a cancer, an inflammatory disease, an autoimmune disease, a wasting disease, a bone disease, a fibro- inflammatory disease, aging, sensence, or age related disorders. In embodiments, the cancer is a cancer that expresses or overexpresses IL-l lRa and / or IL-11. In some embodiments, the cancer may be associated with increased IL-11 , IL-11 Ra and / or gpl30 gene or protein expression. For example, cells of the cancer may have increased expression of IL-11 , IL-11 Ra and / or gp!30 asDocket No. LASS-009 / 01WO 338600-2154 compared to comparable, non-cancerous cells, or may be associated with increased expression of IL-11 , IL-l lRa and / or gpl30 by other cells (e.g. non-cancerous cells) as compared to the level of expression by comparable cells in the absence of a cancer (e.g. in a healthy control subject). In some embodiments, cells of the cancer may be determined to have an increased level of signaling through ERK and / or STAT3 pathways as compared to comparable non-cancerous cells. In embodiments, the cancer displays IL- HRa / IL- 11 -dependent growth, adhesion, migration, invasion, and / or chemoresistance.[000341] In some embodiments, the disease or condition is cancer. Exemplary cancers include, without limitation, bone cancer, prostate cancer, melanoma (e.g., metastatic melanoma), pancreatic cancer, small cell lung cancer, non-small cell lung cancer (NSCLC), mesothelioma, leukemia (e.g., lymphocytic leukemia, chronic myelogenous leukemia, acute myeloid leukemia, relapsed acute myeloid leukemia, hairy cell leukemias, acute lymphoblastic leukemias), lymphoma (e.g., non-Hodgkin’s lymphomas, Hodgkin’s lymphoma), hepatoma (hepatocellular carcinoma), sarcoma, B-cell malignancy, breast cancer, ovarian cancer, colorectal cancer, glioma, glioblastoma multiforme, meningioma, pituitary adenoma, vestibular schwannoma, primary CNS lymphoma, primitive neuroectodermal tumor (medulloblastoma), kidney cancer (e.g., renal cell carcinoma), bladder cancer, uterine cancer, esophageal cancer, brain cancer, head and neck cancers, cervical cancer, testicular cancer, thyroid cancer, and stomach cancer. In specific embodiments, the cancer is a metastatic cancer, for example, which has metastasized to the bone. [000342] In some embodiments, the disease or condition is an inflammatory disease. Non-limiting examples of inflammatory diseases and conditions include airway or lung inflammation (e.g., inflammatory lung disease), asthma, rhinitis, chronic obstructive pulmonary disorder (COPD), dermatitis, psoriasis, hepatitis, gastric inflammation, irritable bowel syndrome (IBS), ulcerative colitis, Crohn’s disease, colitis, diverticulitis, lupus erythematous, nephritis, Parkinson’s disease, multiple sclerosis (MS), Alzheimer’s disease, arthritis, rheumatoid arthritis, sepsis, infection- induced inflammation, cardiovascular diseases such as atherosclerosis and vasculitis, diabetes, inflammatory bowel disease, anaemia, autoimmune thyroiditis, and gout.[000343] In some embodiments, the disease or condition is an autoimmune disease. Non-limiting examples of autoimmune diseases and conditions include arthritis (including rheumatoid arthritis, reactive arthritis), systemic lupus erythematosus (SLE), psoriasis, inflammatory bowel disease (IBD), ulcerative colitis, Crohn’s disease, encephalomyelitis, uveitis, myasthenia gravis, multiple sclerosis, insulin dependent diabetes, Addison’s disease, celiac disease, chronic fatigue syndrome,Docket No. LASS-009 / 01WO 338600-2154 autoimmune hepatitis, autoimmune alopecia, ankylosing spondylitis, fibromyalgia, pemphigus vulgaris, Sjogren’s syndrome, Kawasaki’s Disease, hyperthyroidism / Graves’ disease, hypothyroidism / Hashimoto’s disease, endometriosis, scleroderma, pernicious anemia, Goodpasture syndrome, Guillain-Barre syndrome, Wegener’s disease, glomerulonephritis, aplastic anemia (including multiply transfused aplastic anemia patients), paroxysmal nocturnal hemoglobinuria, myelodysplastic syndrome, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, Evan’s syndrome, Factor VIII inhibitor syndrome, systemic vasculitis, dermatomyositis, polymyositis, rheumatic fever, autoimmune lymphoproliferative syndrome (ALPS), autoimmune bullous pemphigoid, Parkinson’s disease, sarcoidosis, vitiligo, primary biliary cirrhosis, and autoimmune myocarditis.[000344] In some embodiments, the disease or condition is a wasting disease. Non-limiting examples of wasting diseases and conditions include cachexia, including cachexia associated with cancer or renal failure, and sarcopenia. In some embodiments, the disease or condition is a bone disease. Non-limiting examples of bone diseases and conditions include osteoporosis (including post-menopausal osteoporosis), bone fracture, Paget’s disease of bone, and bone resorption / damage associated with cancer or cancer therapy, including chemotherapy, hormone ablation, and hormone inhibition.[000345] In some embodiments, the disease or condition is a fibro-inflammatory disease. Examples include fibrosis of the lungs, cardiovascular system, liver, brain, joints (e.g., knee, hip, ankle, foot joints, shoulder, elbow, wrist, hand joints, spinal vertebrae), intestine, skin, kidney, liver, thyroid, bone marrow, retroperitoneum, or eye (see, for example, Schafer et al., Nature. 552: 110-115, 2017; and Ng et al., Sci Transl Med. 2019 Sep 25;11(511)).[000346] In some embodiments, the fibro-inflammatory disease is selected from fibrothorax, pulmonary fibrosis (for example, cystic fibrosis, interstitial lung disease (ILD), autosomal recessive genetic disease such as Hermansky-Pudlak syndrome type 1, 2, 3, 4, 5, 6, 7, or 8), and radiation-induced lung injury. In some embodiments, the pulmonary fibrosis is related to ILD, for example, idiopathic or secondary ILD. Examples of idiopathic ILD include idiopathic pulmonary fibrosis (IPF), desquamative interstitial pneumonia (DIP), acute interstitial pneumonia (AIP) also known as Hamman-Rich syndrome, nonspecific interstitial pneumonia (NSIP), respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), cryptogenic organizing pneumonia (COP), and lymphoid interstitial pneumonia (LIP). General examples of secondary ILD include ILD related to connective tissue and autoimmune diseases (for example, sarcoidosis, rheumatoidDocket No. LASS-009 / 01WO 338600-2154 arthritis, systemic lupus erythematosus, systemic sclerosis, polymyositis, dermatomyositis, anti synthetase syndrome), inhaled substances (for example, silicosis, asbestosis, berylliosis, industrial printing chemicals, chronic hypersensitivity pneumonitis), drugs (drug-induced ILD, for example, antibiotics, chemotherapeutics, anti -arrhythmic agents), infections (for example, SARS CoV-2, atypical pneumonia, pneumocystis pneumonia, tuberculosis, Chlamydia trachomatis, respiratory syncytial virus), malignancies (lymphangitic carcinomatosis), and pediatric ILDs such as diffuse developmental disorders, growth abnormalities deficient alveolarization, infant conditions of undefined cause, and ILD related to alveolar surfactant region.[000347] In some embodiments, the fibro-inflammatory disease is myocardial fibrosis (for example, interstitial fibrosis, replacement fibrosis). In some embodiments, the fibro-inflammatory disease is thyroid eye disease (TED).[000348] In some embodiments, the disease or condition is an age-related disease or disorder. In some embodiments, the age related disease or disorder is selected from the group consisting of cardiovascular disease (e.g., atherosclerosis, hypertension, heart failure, coronary artery disease), musculoskeletal disorders (e.g., osteoarthritis, osteoporosis, sarcopenia), neurodegenerative disease (e.g., Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s disease), metabolic disorders (e.g., type 2 diabetes mellitus, metabolic syndrome, dyslipidemia, non-alcoholic fatty liver disease (NAFLD)), ophthalmological disorders, (e.g., age- related macular degeneration (AMD), cataracts, glaucoma), pulmonary disorders (e.g., chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF)), hematologic disorders (e.g., anemia of aging, myelodysplastic syndromes), renal disorders (e.g., chronic kidney disease, age-related nephrosclerosis), immune disorders (e.g., immunosenescence, chronic inflammation), skin and connective tissue disorders (e.g., wrinkles, skin thinning, photoaging, age- related fibrosis), cancer (e.g. breast cancer, prostate cancer, colorectal cancer), and endocrine disorders (e.g., hypogonadism, age-related hormone decline). In some embodiments, the age- related disease or disorder is associated with elevated levels of IL-11.[000349] Some embodiments relate to methods of treating, ameliorating the symptoms of, and / or slowing the progession of aging, age related diseases and disorders, cellular aging or senescence in a subject in need thereof. In some embodiments, the subject has elevated levels of IL-11.[000350] In some embodiments, the antibodies of the disclosure are administered to a subject in order to extend or prolong the lifespan of a subject. In some embodiments, the antibodies of the disclosure are administered to a subject in order to slow, prevent, or reverse theDocket No. LASS-009 / 01WO 338600-2154 development / presence of senescence and / or the senescent cells. In some embodiments, the antibodies of the disclosure reduce cellular senescence markers, alleviate chronic infomamation associated with aging, and / or enhance overall tissue health.[000351] Administration may be achieved by a variety of different routes, including oral, parenteral, nasal, intravenous, ocular, intradermal, intramuscular, subcutaneous, installation into the bladder, transdermal, inhalation, sublingual, buccal, rectal, vaginal or topical. Preferred modes of administration depend upon the nature of the condition to be treated or prevented. Particular embodiments include administration by IV infusion or subcuatenous adminstration.[000352] In another aspect, the present disclosure provides a method of inhibiting one or more of hyaluronan production, IL-6 production, and MCP-1 production by a cell, comprising contacting the cell with an antibody described herein or a pharmaceutical composition described herein.[000353] In another aspect, the present disclosure provides a method of inhibiting one or more of hyaluronan production, IL-6 production, and MCP-1 production in a subject, comprising administering to the subject a therapeutically effective amount of an antibody described herein or a pharmaceutical composition described herein.[000354] In another aspect, the present disclosure provides a composition comprising an antibody described herein or a pharmaceutical composition described herein, for use in the treatment of a disease or condition. In embodiments, the disease or condition is a cancer, an inflammatory disease, an autoimmune disease, a wasting disease, a bone disease, an age-related disease or disorder, or a fibro-inflammatory disease.ENUMERATED EMBODIMENTS[000355] Provided are non-limited enumerated embodiments of the disclosure.[000356] Embodiment 1. An antibody specific for interleukin- 11 (IL-11), wherein the antibody blocks or interferes with IL-11 signaling, and wherein the antibody comprises a complementarity determining region (CDR) sequence combination of:(a) SEQ ID NOS: 657-662, wherein Xi = T, S, V, I, L, or D; X2= V, F, or I; X3= S, Y, A, H, V, G, S, F, N, P, or D; X4= A, G, S, L, or P; X5= V, P, T, L, S, A, G, Q, L, R, M, or H; X6= Q, V, T, D, R, A, S, or G; X7= E, K, R, V, M, or L; Xs = M, N, T, S, E, or R; X9= S, G, N, L, K, or I; Xio = F, H, N, or T; Xu = F, V, or A; X12 = L, V, or F; X13 = E, Q, T, or D; Xi4= R, F, S, N, G, H, I, L, V, Q, M, T, A, or Y; X15 = H, Y, V, S, F, D, E, T, A, M, or Q; Xi6= N, G, H, D,Docket No. LASS-009 / 01WO 338600-2154Y, K, Q, E, T, or S; X17 = I, L, or F; and Xis = D, S, A, or P; or(b) SEQ ID NOS: 665-670, wherein Xi = R, N, F, L, V, Y, H, M, K, A, E, or Q; X2= Y, F, N, or H; X3= F, N, or H; X4= D or G; X5= V, I, or Y; X6= D; Xs = I or Y; X9= S; Xio= A, N or V; Xu = M or L; X12 = F or S; X13 = S, F, H, or D; Xi4= T or K; X15 = L, R, or V; Xi6= Q, M, or N; X17 = I, F, H, G, V, Y, R, T, or A; Xis = Y or S; X19 = A; X20 = V, E, or M; X21 = F; X22 = N, V, or I; X23 = R, Y, K, or A.[000357] Embodiment 2. An antibody specific for interleukin- 11 (IL-11), wherein the blocks or interferes with IL-11 signaling, and wherein the antibody comprises:(a) a heavy chain variable region (VH) comprising SEQ ID NO: 663; wherein Xi = T, S, V, I, L, or D; X2= V, F, or I; X3= S, Y, A, H, V, G, S, F, N, P, or D; X4= A, G, S, L, or P; X5= V, P, T, L, S, A, G, Q, L, R, M, or H; X6= Q, V, T, D, R, A, S, or G; X7 = E, K, R, V, M, or L; Xs = M, N, T, S, E, or R; X9 = S, G, N, L, K, or I; X10 = F, H, N, or T; X11 = F, V, or A; X12 = L, V, or F; X13 = E, Q, T, or D; Xi4= R, F, S, N, G, H, I, L, V, Q, M, T, A, or Y; and a light chain variable region (VL) comprising SEQ ID NO: 664; wherein X15 = H, Y, V,S, F, D, E, T, A, M, or Q; Xi6= N, G, H, D, Y, K, Q, E, T, or S; X17 = I, L, or F; and Xis = D, S, A, or P; or(b) a VH comprising SEQ ID NO : 671 ; wherein Xi = R, N, F, L, V, Y, H, M, K, A, E, or Q; X2= Y, F, N, or H; X3= F, N, or H; X4= D or G; X5= V, I, or Y; X6= D; X7= R, K, E, M,T, A, or G; Xs = I or Y; X9= S; X10 = A, N or V; X11 = M or L; X12 = F or S; X13 = S, F, H, or D; Xi4= T or K; X15 = L, R, or V; Xi6= Q, M, or N; X17 = I, F, H, G, V, Y, R, T, or A; Xis = Y or S; X19 = A; X20 = V, E, or M; X21 = F; X22 = N, V, or I; X23 = R, Y, K, or A; and a VL comprising SEQ ID NO: 672; wherein X24= A, S, G, or L; X25 = T or F.[000358] Embodiment 3. An antibody specific for interleukin- 11 (IL-11), wherein the antibody blocks or interferes with IL-11 signaling, and wherein the antibody comprises a complementarity determining region (CDR) sequence combination selected from the group consisting of:(a) SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6;(b) SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12;(c) SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO:Docket No. LASS-009 / 01WO 338600-215417, and SEQ ID NO: 18;(d) SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24;(e) SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, and SEQ ID NO: 30;(I) SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, and SEQ ID NO: 36;(g) SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, and SEQ ID NO: 42;(h) SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, and SEQ ID NO: 48;(i) SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, and SEQ ID NO: 54;0) SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, and SEQ ID NO: 60;(k) SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, and SEQ ID NO: 66;(l) SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72;(m) SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, and SEQ ID NO: 78;(n) SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, and SEQ ID NO: 84;(o) SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, and SEQ ID NO: 90;(p) SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, and SEQ ID NO: 96;(q) SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, and SEQ ID NO: 102;(r) SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, and SEQ ID NO: 108;(s) SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ IDDocket No. LASS-009 / 01WO 338600-2154NO: 113, and SEQ ID NO: 114;(t) SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, and SEQ ID NO: 120;(u) SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, and SEQ ID NO: 126;(v) SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, and SEQ ID NO: 132;(w) SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, and SEQ ID NO: 138;(x) SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, and SEQ ID NO: 144;(y) SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, and SEQ ID NO: 150;(z) SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, and SEQ ID NO: 156;(aa) SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, and SEQ ID NO: 162;(bb) SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, and SEQ ID NO: 168;(cc) SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, and SEQ ID NO: 174;(dd) SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178, SEQ ID NO: 179, and SEQ ID NO: 180;(ee) SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 183, SEQ ID NO: 184, SEQ ID NO: 185, and SEQ ID NO: 186;(ff) SEQ ID NO: 187, SEQ ID NO: 188, SEQ ID NO: 189, SEQ ID NO: 190, SEQ ID NO: 191, and SEQ ID NO: 192;(gg) SEQ ID NO: 193, SEQ ID NO: 194, SEQ ID NO: 195, SEQ ID NO: 196, SEQ ID NO: 197, and SEQ ID NO: 198;(hh) SEQ ID NO: 199, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID NO: 202, SEQ ID NO: 203, and SEQ ID NO: 204;(ii) SEQ ID NO: 205, SEQ ID NO: 206, SEQ ID NO: 207, SEQ ID NO: 208, SEQ IDDocket No. LASS-009 / 01WO 338600-2154NO: 209, and SEQ ID NO: 210;(jj) SEQ ID NO: 211, SEQ ID NO: 212, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215, and SEQ ID NO: 216;(kk) SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, and SEQ ID NO: 222;(11) SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, and SEQ ID NO: 228;(mm) SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, and SEQ ID NO: 234;(nn) SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, and SEQ ID NO: 240;(oo) SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, and SEQ ID NO: 246;(pp) SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, and SEQ ID NO: 252;(qq) SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, and SEQ ID NO: 258;(rr) SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, and SEQ ID NO: 264;(ss) SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, and SEQ ID NO: 270;(tt) SEQ ID NO: 271, SEQ ID NO: 272, SEQ ID NO: 273, SEQ ID NO: 274, SEQ ID NO: 275, and SEQ ID NO: 276;(uu) SEQ ID NO: 277, SEQ ID NO: 278, SEQ ID NO: 279, SEQ ID NO: 280, SEQ ID NO: 281, and SEQ ID NO: 282;(vv) SEQ ID NO: 283, SEQ ID NO: 284, SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 287, and SEQ ID NO: 288;(ww) SEQ ID NO: 289, SEQ ID NO: 290, SEQ ID NO: 291, SEQ ID NO: 292, SEQ ID NO: 293, and SEQ ID NO: 294;(xx) SEQ ID NO: 295, SEQ ID NO: 296, SEQ ID NO: 297, SEQ ID NO: 298, SEQ ID NO: 299, and SEQ ID NO: 300;(yy) SEQ ID NO: 301, SEQ ID NO: 302, SEQ ID NO: 303, SEQ ID NO: 304, SEQ IDDocket No. LASS-009 / 01WO 338600-2154NO: 305, and SEQ ID NO: 306;(zz) SEQ ID NO: 307, SEQ ID NO: 308, SEQ ID NO: 309, SEQ ID NO: 310, SEQ ID NO: 311, and SEQ ID NO: 312;(aaa) SEQ ID NO: 313, SEQ ID NO: 314, SEQ ID NO: 315, SEQ ID NO: 316, SEQ ID NO: 317, and SEQ ID NO: 318;(bbb) SEQ ID NO: 319, SEQ ID NO: 320, SEQ ID NO: 321, SEQ ID NO: 322, SEQ ID NO: 323, and SEQ ID NO: 324;(ccc) SEQ ID NO: 325, SEQ ID NO: 326, SEQ ID NO: 327, SEQ ID NO: 328, SEQ ID NO: 329, and SEQ ID NO: 330;(ddd) SEQ ID NO: 331, SEQ ID NO: 332, SEQ ID NO: 333, SEQ ID NO: 334, SEQ ID NO: 335, and SEQ ID NO: 336;(eee) SEQ ID NO: 337, SEQ ID NO: 338, SEQ ID NO: 339, SEQ ID NO: 340, SEQ ID NO: 341, and SEQ ID NO: 342;(fff) SEQ ID NO: 343, SEQ ID NO: 344, SEQ ID NO: 345, SEQ ID NO: 346, SEQ ID NO: 347, and SEQ ID NO: 348;(ggg) SEQ ID NO: 349, SEQ ID NO: 350, SEQ ID NO: 351, SEQ ID NO: 352, SEQ ID NO: 353, and SEQ ID NO: 354;(hhh) SEQ ID NO: 355, SEQ ID NO: 356, SEQ ID NO: 357, SEQ ID NO: 358, SEQ ID NO: 359, and SEQ ID NO: 360;(iii) SEQ ID NO: 361, SEQ ID NO: 362, SEQ ID NO: 363, SEQ ID NO: 364, SEQ ID NO: 365, and SEQ ID NO: 366;(jjj) SEQ ID NO: 367, SEQ ID NO: 368, SEQ ID NO: 369, SEQ ID NO: 370, SEQ ID NO: 371, and SEQ ID NO: 372;(kkk) SEQ ID NO: 373, SEQ ID NO: 374, SEQ ID NO: 375, SEQ ID NO: 376, SEQ ID NO: 377, and SEQ ID NO: 378;(111) SEQ ID NO: 379, SEQ ID NO: 380, SEQ ID NO: 381, SEQ ID NO: 382, SEQ ID NO: 383, and SEQ ID NO: 384;(mmm) SEQ ID NO: 385, SEQ ID NO: 386, SEQ ID NO: 387, SEQ ID NO: 388, SEQ ID NO: 389, and SEQ ID NO: 390;(nnn) SEQ ID NO: 391, SEQ ID NO: 392, SEQ ID NO: 393, SEQ ID NO: 394, SEQ ID NO: 395, and SEQ ID NO: 396;(ooo) SEQ ID NO: 397, SEQ ID NO: 398, SEQ ID NO: 399, SEQ ID NO: 400, SEQ IDDocket No. LASS-009 / 01WO 338600-2154NO: 401, and SEQ ID NO: 402;(ppp) SEQ ID NO: 403, SEQ ID NO: 404, SEQ ID NO: 405, SEQ ID NO: 406, SEQ ID NO: 407, and SEQ ID NO: 408;(qqq) SEQ ID NO: 409, SEQ ID NO: 410, SEQ ID NO: 411, SEQ ID NO: 412, SEQ ID NO: 413, and SEQ ID NO: 414;(rrr) SEQ ID NO: 415, SEQ ID NO: 416, SEQ ID NO: 417, SEQ ID NO: 418, SEQ ID NO: 419, and SEQ ID NO: 420;(sss) SEQ ID NO: 421, SEQ ID NO: 422, SEQ ID NO: 423, SEQ ID NO: 424, SEQ ID NO: 425, and SEQ ID NO: 426;(ttt) SEQ ID NO: 427, SEQ ID NO: 428, SEQ ID NO: 429, SEQ ID NO: 430, SEQ ID NO: 431, and SEQ ID NO: 432;(uuu) SEQ ID NO: 433, SEQ ID NO: 434, SEQ ID NO: 435, SEQ ID NO: 436, SEQ ID NO: 437, and SEQ ID NO: 438;(vvv) SEQ ID NO: 439, SEQ ID NO: 440, SEQ ID NO: 441, SEQ ID NO: 442, SEQ ID NO: 443, and SEQ ID NO: 444;(www) SEQ ID NO: 445, SEQ ID NO: 446, SEQ ID NO: 447, SEQ ID NO: 448, SEQ ID NO: 449, and SEQ ID NO: 450;(xxx) SEQ ID NO: 451, SEQ ID NO: 452, SEQ ID NO: 453, SEQ ID NO: 454, SEQ ID NO: 455, and SEQ ID NO: 456;(yyy) SEQ ID NO: 457, SEQ ID NO: 458, SEQ ID NO: 459, SEQ ID NO: 460, SEQ ID NO: 461, and SEQ ID NO: 462;(zzz) SEQ ID NO: 463, SEQ ID NO: 464, SEQ ID NO: 465, SEQ ID NO: 466, SEQ ID NO: 467, and SEQ ID NO: 468;(aaaa) SEQ ID NO: 469, SEQ ID NO: 470, SEQ ID NO: 471, SEQ ID NO: 472, SEQ ID NO: 473, and SEQ ID NO: 474;(bbbb) SEQ ID NO: 475, SEQ ID NO: 476, SEQ ID NO: 477, SEQ ID NO: 478, SEQ ID NO: 479, and SEQ ID NO: 480;(cccc) SEQ ID NO: 481, SEQ ID NO: 482, SEQ ID NO: 483, SEQ ID NO: 484, SEQ ID NO: 485, and SEQ ID NO: 486; and(dddd) SEQ ID NO: 487, SEQ ID NO: 488, SEQ ID NO: 489, SEQ ID NO: 490, SEQ ID NO: 491, and SEQ ID NO: 492.[000359] Embodiment 4. An antibody specific for interleukin- 11 (IL-11), wherein the antibodyDocket No. LASS-009 / 01WO 338600-2154 blocks or interferes with IL- 11 signaling, and wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein:(a) the VH comprises a sequence according to SEQ ID NO: 493 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 494 or a sequence at least 70% identical thereto;(b) the VH comprises a sequence according to SEQ ID NO: 495 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 496 or a sequence at least 70% identical thereto;(c) the VH comprises a sequence according to SEQ ID NO: 497 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 498 or a sequence at least 70% identical thereto;(d) the VH comprises a sequence according to SEQ ID NO: 499 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 500 or a sequence at least 70% identical thereto;(e) the VH comprises a sequence according to SEQ ID NO: 501 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 502 or a sequence at least 70% identical thereto;(I) the VH comprises a sequence according to SEQ ID NO: 503 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 504 or a sequence at least 70% identical thereto;(g) the VH comprises a sequence according to SEQ ID NO: 505 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 506 or a sequence at least 70% identical thereto;(h) the VH comprises a sequence according to SEQ ID NO: 507 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 508 or a sequence at least 70% identical thereto;(i) the VH comprises a sequence according to SEQ ID NO: 509 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 510 or a sequence at least 70% identical thereto;(j) the VH comprises a sequence according to SEQ ID NO: 511 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 512 or a sequence at least 70% identical thereto;Docket No. LASS-009 / 01WO 338600-2154(k) the VH comprises a sequence according to SEQ ID NO: 513 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 514 or a sequence at least 70% identical thereto;(l) the VH comprises a sequence according to SEQ ID NO: 515 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 516 or a sequence at least 70% identical thereto;(m) the VH comprises a sequence according to SEQ ID NO: 517 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 518 or a sequence at least 70% identical thereto;(n) the VH comprises a sequence according to SEQ ID NO: 519 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 520 or a sequence at least 70% identical thereto;(o) the VH comprises a sequence according to SEQ ID NO: 521 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 522 or a sequence at least 70% identical thereto;(p) the VH comprises a sequence according to SEQ ID NO: 523 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 524 or a sequence at least 70% identical thereto;(q) the VH comprises a sequence according to SEQ ID NO: 525 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 526 or a sequence at least 70% identical thereto;(r) the VH comprises a sequence according to SEQ ID NO: 527 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 528 or a sequence at least 70% identical thereto;(s) the VH comprises a sequence according to SEQ ID NO: 529 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 530 or a sequence at least 70% identical thereto;(t) the VH comprises a sequence according to SEQ ID NO: 531 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 532 or a sequence at least 70% identical thereto;(u) the VH comprises a sequence according to SEQ ID NO: 533 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 534 or aDocket No. LASS-009 / 01WO 338600-2154 sequence at least 70% identical thereto;(v) the VH comprises a sequence according to SEQ ID NO: 535 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 536 or a sequence at least 70% identical thereto;(w) the VH comprises a sequence according to SEQ ID NO: 537 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 538 or a sequence at least 70% identical thereto;(x) the VH comprises a sequence according to SEQ ID NO: 539 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 540 or a sequence at least 70% identical thereto;(y) the VH comprises a sequence according to SEQ ID NO: 541 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 542 or a sequence at least 70% identical thereto;(z) the VH comprises a sequence according to SEQ ID NO: 543 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 544 or a sequence at least 70% identical thereto;(aa) the VH comprises a sequence according to SEQ ID NO: 545 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 546 or a sequence at least 70% identical thereto;(bb) the VH comprises a sequence according to SEQ ID NO: 547 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 548 or a sequence at least 70% identical thereto;(cc) the VH comprises a sequence according to SEQ ID NO: 549 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 550 or a sequence at least 70% identical thereto;(dd) the VH comprises a sequence according to SEQ ID NO: 551 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 552 or a sequence at least 70% identical thereto;(ee) the VH comprises a sequence according to SEQ ID NO: 553 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 554 or a sequence at least 70% identical thereto;(ff) the VH comprises a sequence according to SEQ ID NO: 555 or a sequence at leastDocket No. LASS-009 / 01WO 338600-215470% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 556 or a sequence at least 70% identical thereto;(gg) the VH comprises a sequence according to SEQ ID NO: 557 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 558 or a sequence at least 70% identical thereto;(hh) the VH comprises a sequence according to SEQ ID NO: 559 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 560 or a sequence at least 70% identical thereto;(ii) the VH comprises a sequence according to SEQ ID NO: 561 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 562 or a sequence at least 70% identical thereto;(jj) the VH comprises a sequence according to SEQ ID NO: 563 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 564 or a sequence at least 70% identical thereto;(kk) the VH comprises a sequence according to SEQ ID NO: 565 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 566 or a sequence at least 70% identical thereto;(11) the VH comprises a sequence according to SEQ ID NO: 567 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 568 or a sequence at least 70% identical thereto;(mm) the VH comprises a sequence according to SEQ ID NO: 569 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 570 or a sequence at least 70% identical thereto;(nn) the VH comprises a sequence according to SEQ ID NO: 571 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 572 or a sequence at least 70% identical thereto;(oo) the VH comprises a sequence according to SEQ ID NO: 573 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 574 or a sequence at least 70% identical thereto;(PP) the VH comprises a sequence according to SEQ ID NO: 575 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 576 or a sequence at least 70% identical thereto;Docket No. LASS-009 / 01WO 338600-2154(qq) the VH comprises a sequence according to SEQ ID NO: 577 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 578 or a sequence at least 70% identical thereto;(rr) the VH comprises a sequence according to SEQ ID NO: 579 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 580 or a sequence at least 70% identical thereto;(ss) the VH comprises a sequence according to SEQ ID NO: 581 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 582 or a sequence at least 70% identical thereto;(tt) the VH comprises a sequence according to SEQ ID NO: 583 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 584 or a sequence at least 70% identical thereto;(uu) the VH comprises a sequence according to SEQ ID NO: 585 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 586 or a sequence at least 70% identical thereto;(vv) the VH comprises a sequence according to SEQ ID NO: 587 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 588 or a sequence at least 70% identical thereto;(ww) the VH comprises a sequence according to SEQ ID NO: 589 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 590 or a sequence at least 70% identical thereto;(xx) the VH comprises a sequence according to SEQ ID NO: 591 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 592 or a sequence at least 70% identical thereto;(yy) the VH comprises a sequence according to SEQ ID NO: 593 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 594 or a sequence at least 70% identical thereto;(zz) the VH comprises a sequence according to SEQ ID NO: 595 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 596 or a sequence at least 70% identical thereto;(aaa) the VH comprises a sequence according to SEQ ID NO: 597 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 598 or aDocket No. LASS-009 / 01WO 338600-2154 sequence at least 70% identical thereto;(bbb) the VH comprises a sequence according to SEQ ID NO: 599 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 600 or a sequence at least 70% identical thereto;(ccc) the VH comprises a sequence according to SEQ ID NO: 601 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 602 or a sequence at least 70% identical thereto;(ddd) the VH comprises a sequence according to SEQ ID NO: 603 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 604 or a sequence at least 70% identical thereto;(eee) the VH comprises a sequence according to SEQ ID NO: 605 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 606 or a sequence at least 70% identical thereto;(fff) the VH comprises a sequence according to SEQ ID NO: 607 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 608 or a sequence at least 70% identical thereto;(ggg) the VH comprises a sequence according to SEQ ID NO: 609 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 610 or a sequence at least 70% identical thereto;(hhh) the VH comprises a sequence according to SEQ ID NO: 611 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 612 or a sequence at least 70% identical thereto;(iii) the VH comprises a sequence according to SEQ ID NO: 613 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 614 or a sequence at least 70% identical thereto;(jjj) the VH comprises a sequence according to SEQ ID NO: 615 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 616 or a sequence at least 70% identical thereto;(kkk) the VH comprises a sequence according to SEQ ID NO: 617 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 618 or a sequence at least 70% identical thereto;(Hl) the VH comprises a sequence according to SEQ ID NO: 619 or a sequence at leastDocket No. LASS-009 / 01WO 338600-215470% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 620 or a sequence at least 70% identical thereto;(mmm) the VH comprises a sequence according to SEQ ID NO: 621 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 622 or a sequence at least 70% identical thereto;(nnn) the VH comprises a sequence according to SEQ ID NO: 623 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 624 or a sequence at least 70% identical thereto;(ooo) the VH comprises a sequence according to SEQ ID NO: 625 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 626 or a sequence at least 70% identical thereto;(ppp) the VH comprises a sequence according to SEQ ID NO: 627 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 628 or a sequence at least 70% identical thereto;(qqq) the VH comprises a sequence according to SEQ ID NO: 629 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 630 or a sequence at least 70% identical thereto;(rrr) the VH comprises a sequence according to SEQ ID NO: 631 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 632 or a sequence at least 70% identical thereto;(sss) the VH comprises a sequence according to SEQ ID NO: 633 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 634 or a sequence at least 70% identical thereto;(ttt) the VH comprises a sequence according to SEQ ID NO: 635 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 636 or a sequence at least 70% identical thereto;(uuu) the VH comprises a sequence according to SEQ ID NO: 637 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 638 or a sequence at least 70% identical thereto;(vvv) the VH comprises a sequence according to SEQ ID NO: 639 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 640 or a sequence at least 70% identical thereto;Docket No. LASS-009 / 01WO 338600-2154(www)the VH comprises a sequence according to SEQ ID NO: 641 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 642 or a sequence at least 70% identical thereto;(xxx) the VH comprises a sequence according to SEQ ID NO: 643 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 644 or a sequence at least 70% identical thereto;(yyy) the VH comprises a sequence according to SEQ ID NO: 645 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 646 or a sequence at least 70% identical thereto;(zzz) the VH comprises a sequence according to SEQ ID NO: 647 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 648 or a sequence at least 70% identical thereto;(aaaa) the VH comprises a sequence according to SEQ ID NO: 649 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 650 or a sequence at least 70% identical thereto;(bbbb)the VH comprises a sequence according to SEQ ID NO: 651 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 652 or a sequence at least 70% identical thereto;(cccc) the VH comprises a sequence according to SEQ ID NO: 653 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 654 or a sequence at least 70% identical thereto; or(dddd)the VH comprises a sequence according to SEQ ID NO: 655 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 656 or a sequence at least 70% identical thereto.[000360] Embodiment 5. The antibody of any one of embodiments 1-4, wherein the antibody is a monoclonal antibody.[000361] Embodiment 6. The antibody of any one of embodiments 1-4, wherein the antibody is an antibody fragment.[000362] Embodiment 7. The antibody of any one of embodiments 1-4, wherein the antibody is a human antibody.[000363] Embodiment 8. The antibody of any one of embodiments 1-4, wherein the antibody is a humanized antibody.Docket No. LASS-009 / 01WO 338600-2154[000364] Embodiment 9. The antibody of any one of embodiments 1-4, wherein the antibody is a chimeric antibody.[000365] Embodiment 10. The antibody of any one of embodiments 1-9, wherein the antibody comprises an Fc domain.[000366] Embodiment 11. The antibody of embodiment 10, wherein the Fc domain is IgA (including subclasses IgAl and IgA2), IgD, IgE, IgG (including subclasses IgGl, IgG2, IgG3, and IgG4), or IgM Fc domain, optionally a human Fc domain, or a hybrid and / or variant thereof.[000367] Embodiment 12. A pharmaceutical composition comprising the antibody of any one of embodiments 1-11, and a pharmaceutically-acceptable carrier.[000368] Embodiment 13. A nucleic acid encoding the antibody of any one of embodiments 1-11. [000369] Embodiment 14. A vector comprising the nucleic acid of embodiment 13.[000370] Embodiment 15. A method of treating a disease or condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody of any one of embodiments 1-11 or the pharmaceutical composition of embodiment 12.[000371] Embodiment 16. The method of embodiment 15, wherein the disease or condition is an IL- 11 -associated or IL- 11 -mediated disease or condition.[000372] Embodiment 17. The method of embodiment 15, wherein the disease or condition is a cancer, an inflammatory disease, an autoimmune disease, a wasting disease, a bone disease, an age-related disease or disorder, or a fibro-inflammatory disease.[000373] Embodiment 18. The method of embodiment 17, wherein the disease is a cancer, optionally a cancer that expresses or overexpresses IL-1 IRa and / or IL-11, optionally wherein the cancer displays IL- HRa / IL- 11 -dependent growth, adhesion, migration, invasion, and / or chemoresistance.[000374] Embodiment 19. The method of embodiment 17 or 18, wherein the cancer is selected from one or more of bone cancer, prostate cancer, melanoma (e.g., metastatic melanoma), pancreatic cancer, small cell lung cancer, non-small cell lung cancer (NSCLC), mesothelioma, leukemia (e.g., lymphocytic leukemia, chronic myelogenous leukemia, acute myeloid leukemia, relapsed acute myeloid leukemia, hairy cell leukemias, acute lymphoblastic leukemias), lymphoma (e.g., non-Hodgkin’s lymphomas, Hodgkin’s lymphoma), hepatoma (hepatocellular carcinoma), sarcoma, B-cell malignancy, breast cancer, ovarian cancer, colorectal cancer, glioma, glioblastoma multiforme, meningioma, pituitary adenoma, vestibular schwannoma, primary CNS lymphoma, primitive neuroectodermal tumor (medulloblastoma), kidney cancer (e.g., renal cellDocket No. LASS-009 / 01WO 338600-2154 carcinoma), bladder cancer, uterine cancer, esophageal cancer, brain cancer, head and neck cancers, cervical cancer, testicular cancer, thyroid cancer, and stomach cancer.[000375] Embodiment 20. The method of any one of embodiments 17-19, wherein the cancer is a metastatic cancer, optionally a metastatic cancer which has metastasized to the bone.[000376] Embodiment 21. The method of claim 17, wherein the inflammatory disease is selected from one or more of airway or lung inflammation (e.g., inflammatory lung disease), asthma, rhinitis, chronic obstructive pulmonary disorder (COPD), dermatitis, psoriasis, hepatitis, gastric inflammation, irritable bowel syndrome (IBS), ulcerative colitis, Crohn’s disease, colitis, diverticulitis, lupus erythematous, nephritis, Parkinson’s disease, multiple sclerosis (MS), Alzheimer’s disease, arthritis, rheumatoid arthritis, sepsis, infection-induced inflammation, cardiovascular diseases such as atherosclerosis and vasculitis, diabetes, and gout.[000377] Embodiment 22. The method of embodiment 17, wherein the autoimmune disease is selected from one or more of arthritis (including rheumatoid arthritis, reactive arthritis), systemic lupus erythematosus (SLE), psoriasis, inflammatory bowel disease (IBD), ulcerative colitis, Crohn’s disease, encephalomyelitis, uveitis, myasthenia gravis, multiple sclerosis, insulin dependent diabetes, Addison’s disease, celiac disease, chronic fatigue syndrome, autoimmune hepatitis, autoimmune alopecia, ankylosing spondylitis, fibromyalgia, pemphigus vulgaris, Sjogren’s syndrome, Kawasaki’s Disease, hyperthyroidism / Graves’ disease, hypothyroidism / Hashimoto’s disease, endometriosis, scleroderma, pernicious anemia, Goodpasture syndrome, Guillain-Barre syndrome, Wegener’s disease, glomerulonephritis, aplastic anemia (including multiply transfused aplastic anemia patients), paroxysmal nocturnal hemoglobinuria, myelodysplastic syndrome, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, Evan’s syndrome, Factor VIII inhibitor syndrome, systemic vasculitis, dermatomyositis, polymyositis, rheumatic fever, autoimmune lymphoproliferative syndrome (ALPS), autoimmune bullous pemphigoid, Parkinson’s disease, sarcoidosis, vitiligo, primary biliary cirrhosis, and autoimmune myocarditis.[000378] Embodiment 23. The method of embodiment 17, wherein the wasting disease is selected from one or more of cachexia, optionally cachexia associated with cancer or renal failure, and sarcopenia.[000379] Embodiment 24. The method of embodiment 17, wherein the bone disease is selected from osteoporosis (including post-menopausal osteoporosis), bone fracture, Paget’s disease of bone, and bone resorption / damage associated with cancer or cancer therapy, includingDocket No. LASS-009 / 01WO 338600-2154 chemotherapy, hormone ablation, and hormone inhibition.[000380] Embodiment 25. The method of embodiment 17, wherein the fibro-inflammatory disease comprises fibrosis of the lungs, cardiovascular system, liver, brain, joints (optionally knee, hip, ankle, foot joints, shoulder, elbow, wrist, hand joints, or spinal vertebrae), intestine, skin, kidney, liver, thyroid, bone marrow, retroperitoneum, or eye.[000381] Embodiment 26. The method of embodiment 17 or 25, wherein the fibro-inflammatory disease is selected from the group consisting of fibrothorax, pulmonary fibrosis (optionally cystic fibrosis or interstitial lung disease (ILD)), autosomal recessive genetic disease optionally Hermansky-Pudlak syndrome, radiation-induced lung injury, myocardial fibrosis (optionally interstitial fibrosis or replacement fibrosis) and thyroid eye disease (TED).[000382] Embodiment 27. The method of embodiment 26, wherein the ILD is idiopathic ILD, optionally selected from idiopathic pulmonary fibrosis (IPF), desquamative interstitial pneumonia (DIP), acute interstitial pneumonia (AIP) or Hamman-Rich syndrome, nonspecific interstitial pneumonia (NSIP), respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), cryptogenic organizing pneumonia (COP), and lymphoid interstitial pneumonia (LIP).[000383] Embodiment 28. The method of embodiment 26, wherein the ILD is secondary ILD, optionally selected from ILD related to connective tissue and autoimmune diseases (optionally sarcoidosis, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, polymyositis, dermatomyositis, or anti synthetase syndrome), inhaled substances (optionally silicosis, asbestosis, berylliosis, industrial printing chemicals, or chronic hypersensitivity pneumonitis), drugs (optionally antibiotics, chemotherapeutics, or anti-arrhythmic agents), infections (optionally SARS CoV-2, atypical pneumonia, pneumocystis pneumonia, tuberculosis, Chlamydia trachomatis, or respiratory syncytial virus), malignancies (optionally lymphangitic carcinomatosis), and pediatric ILDs (optionally developmental disorders, growth abnormalities deficient alveolarization, infant conditions of undefined cause, and ILD related to alveolar surfactant region).[000384] Embodiment 29. The method of embodiment 17, wherein the age related disease or disorder is selected from the group consisting of cardiovascular disease (optionally atherosclerosis, hypertension, heart failure, coronary artery disease), musculoskeletal disorders (optionally osteoarthritis, osteoporosis, sarcopenia), neurodegenerative disease (optionally Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s disease), metabolic disorders (optionally type 2 diabetes mellitus, metabolic syndrome,Docket No. LASS-009 / 01WO 338600-2154 dyslipidemia, non-alcoholic fatty liver disease (NAFLD)), ophthalmological disorders, (optionally age-related macular degeneration (AMD), cataracts, glaucoma), pulmonary disorders (optionally chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF)), hematologic disorders (optionally anemia of aging, myelodysplastic syndromes), renal disorders (optionally chronic kidney disease, age-related nephrosclerosis), immune disorders (optionally immunosenescence, chronic inflammation), skin and connective tissue disorders (optionally wrinkles, skin thinning, photoaging, age-related fibrosis), cancer (optionally breast cancer, prostate cancer, colorectal cancer), and endocrine disorders (optionally hypogonadism, age-related hormone decline).[000385] Embodiment 30. A method of preventing, ameliorating, or reversing cellular aging or senescence in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody of any one of embodiments 1-11 or the pharmaceutical composition of embodiment 12.[000386] Embodiment 31. A method of inhibiting one or more of hyaluronan production, IL-6 production, and MCP-1 production by a cell, comprising contacting the cell with the antibody of any one of embodiments 1-11 or the pharmaceutical composition of embodiment 12.[000387] Embodiment 32. A method of inhibiting one or more of hyaluronan production, IL-6 production, and MCP-1 production in a subject, comprising administering to the subject a therapeutically effective amount of the antibody of any one of embodiments 1-11 or the pharmaceutical composition of embodiment 12.[000388] Embodiment 33. A composition comprising the antibody of any one of embodiments 1- 11 or the pharmaceutical composition of embodiment 12, for use in the treatment of a disease or condition.[000389] Embodiment 34. The composition for use of embodiment 33, wherein the disease or condition is a cancer, an inflammatory disease, an autoimmune disease, a wasting disease, a bone disease, an age-related disease or disorder, or a fibro-inflammatory disease.[000390]EXAMPLESExample 1: Generation and evaluation of anti-IL-11 mAbs[000391] Methods[000392] Generation of mAbs to IL-11Docket No. LASS-009 / 01WO 338600-2154[000393] Cohorts of DiversimAb™ mice (Abveris Inc.) were immunized with human IL-11- mouse Fc fusion protein. Titers to purified human, cyno, and mouse recombinant IL-11 with His tags were measured by ELISA and mice with high titers were selected for preparation of hybridomas using established techniques. Hybridoma supernatants were tested for binding to human, cyno, and mouse recombinant IL- 11 with His tags in initial screening and positive hits were further tested using biolayer interferometry (Octet analysis) to allow ranking of the antibodies by antigen binding affinity (KD) and whether or not they were potential IL- 11 neutralizing antibodies. Potential neutralization was tested by whether or not IL- 11 binding to soluble IL-11 receptor alpha could take place in the presence of each test antibody, or by inhibition of IL- 11 signaling in a cell-based IL-11 driven pSTAT3 reporter assay.Expression and purification of recombinant antibodies[000394] Expi293F cells from the Expi293 Expression System Kit (Thermo Fisher, cat. No. A14635) were grown in Expi293F expression medium (cat. No. A1435101). Cells were grown to a density of 3-6xl06cells / mL and then counted using a hemocytometer. Plasmid DNA (1.0 ug per 1.0 mL of culture) was diluted in Opti-MEM Reduced Serum Medium (RSM) (cat. No. 31985062). Values of Opti-MEM RSM were taken from manufacturer’s recommendations for transfections. Expifectamine 293 reagent was diluted in Opti-MEM RSM and incubated for 5 mins at room temperature before mixing with diluted plasmid DNA. This mixture was left to incubate for 10-20 minutes at room temperature. While the expifectamine / plasmid DNA complex was incubating, Expi293F cells were diluted to a density of 3xl06cells / mL and added to Erlenmeyer flasks of desired volume (BioPioneer, DGFPC0125S for 125 mL flask). The expifectamine / plasmid DNA complex was then slowly transferred to a shaker flask with Expi293F cells, and the flasks were placed in a shaking incubator with a 25 mm orbital throw (Infors-HT Multitron) at 37 °C, 8% CO2, 125 rpm. 18-22 h post transfection, ExpiFectamine 293 Transfection Enhancer 1 (#100013863) and 2 (#A14350-01) were added to the cells, and the cells were returned to the shaking incubator. Cells were then left to incubate for 4 additional days, then spun down at 4000 x g for 20 minutes in a refrigerated centrifuge and 0.22 um filtered prior to purification.[000395] Antibodies were purified using 5 mL HiTrap MabSelect SuRe (Protein A) columns on an AKTA Explorer FPLC system. Columns were first cleared of any residual bound protein by the addition of 50 mL of 0.1 M glycine, pH 3.0 (elution buffer) followed by 50 mL of 50 mM glycine, 50 mM glycinate pH 8 (binding / washing buffer). Antibodies (25 - 400 mL) were loadedDocket No. LASS-009 / 01WO 338600-2154 onto column at 5 mL / min and further washed with 25 mL equilibration / wash buffer until UV reading reached baseline. Mabs were subsequently eluted by using a 25 mL linear gradient of 0- 100% elution buffer for 2 min at 5 mL / min. Antibody elution was monitored by absorbance at 280 nm. Peak fractions were collected and pooled in a 15 mL conical tube. Material was then buffer exchanged into storage buffer (PBS, pH 7.4) using PD10 columns (Cytiva cat. No. 17085101), and subsequently filter sterilized (GenClone Syringe Filters, cat. No. 25-244 attached to BD 5 mL [cat. No. 309646] and 20 mL [cat. No. 302830] BD Luer-Lok™ syringes) into a 15 mL conical tube and used for subsequent characterization assays.Analysis by size-exclusion HPLC (SEC-HPLC)[000396] SEC-HPLC was performed on a 5 pm particle size, 7.8 mm I.D. X 30 cm TSKgel G3000SWXL and run isocratically using 50 mM sodium phosphate, 200 mM arginine pH 6.8 at a flow rate of 1 mL / minute on an Agilent 1100 HPLC. Detection was at 280 nm using a diode array detector and peaks were integrated using Agilent ChemStation software. SEC- HPLC standards used to calibrate the column consisted of bovine thyroglobulin, bovine IgG, chicken albumin, bovine ribonuclease A and p-aminobenzoic acid (Sigma Aldrich #69385).Analysis of binding affinity by biolayer interferometry (BLI)[000397] Binding kinetic measurements were taken on a Fortebio (now Sartorius) Octet RED96e instrument. mAbs were loaded onto anti-human constant domain (AHC) biosensors (ForteBio) in lOx kinetics buffer consisting of PBS containing 0.1% BSA, 0.02% Tween 20 for 90-120 s to achieve a spectral shift value between 0.8 to 1.2 nm. Association was carried out in the presence of a 2-fold dilution series of hIL-11 and was typically allowed to proceed for 90-120 s; dissociation was generally measured for 300 to 1200 s. Dilution series started at 100 nM for weaker variants or 10 nM for the most potent mAbs. Cross-reactivity to cyno IL-11 and mouse IL-11 was determined using the same methodology with the appropriate species’ IL-11.Preparation of libraries / site-directed mutagenesis[000398] To affinity mature selected antibodies, libraries of variants were prepared focusing on each of the HC and LC CDRs in turn. To accomplish this, each CDR amino acid was replaced in turn with up to 17 amino acid substitutions. Cysteine and tryptophan were not included in theDocket No. LASS-009 / 01WO 338600-2154 libraries so as to not introduce unwanted potential sequence liabilities, nor was the parental amino acid already in position included in the screen. To generate the variants at each position, two sets of mutagenic oligonucleotides (Integrated DNA Technologies (IDT), San Diego) containing the degenerate codons NDT, or VHG, (where N = A / C / G / T; D = A / G / T, V = A / C / G; H = A / C / T) were used for each position (Kille, 2013; Acevedo-Rocha, 2015) paired with appropriate 5’ and 3’ distal oligonucleotides (IDT) designed to permit the amplification and cloning.[000399] PCR was performed with high-fidelity DNA Polymerase (Q5, New England Biolabs) according to the manufacturer’s protocols. Parental plasmids (both heavy and light chains) were diluted to 10 ng / pL and 1 pL was used as template for each 50 pL reaction. V-region gene fragments with degenerate codons as described above, were amplified by PCR and purified (Qiagen PCR purification kit used per manufacturer’s instructions). Gene fragments were assembled into heavy and light chain clones via either overlap extension PCR (OE-PCR) or Gibson cloning. For OE-PCR, fragments were amplified with corresponding forward and reverse primers containing restriction sites (Agel-Nhel for heavy chain, Sbfl-Mfel for light chain) and column purified (Qiagen PCR purification kit). Restriction digests were carried out using high fidelity enzymes (New England Biolabs) and fragments were ligated using T4 DNA ligase (New England Biolabs, Cat # M0202L) into appropriate vectors for heavy and light chain. Empty heavy chain vector contains the majority of the human IgGl constant region with an engineered Nhel site (created by altering wobble positions) 12 amino acids into the constant region. Light chain empty vector contains the majority of the human Kappa constant region with an engineered Mfel site 18 amino acids into the constant region. Gibson Cloning was achieved using the fragments with the same empty vectors (Gibson Assembly® Master Mix Kit, New England Biolabs Cat # ES261 IL). Inserts were normalized to 1 ng / pL and a total of 2 ng of insert DNA is used (1 ng per fragment). 10 pL reaction volume was made up of 5 pL of Gibson Master Mix and QS with purified water. The reaction was incubated at 50 °C for 15-60 minutes.[000400] Ligation products from either OE-PCR or Gibson assembly were transformed into competent E. Coli (Monserate Biotechnology, San Diego) by adding 2-5 pL of the ligation reaction mix to the cells and incubating on ice for 5 minutes. Cells were heat shocked at 42 °C for 30 seconds and placed on ice. 250 pL of SOC media (BioPioneer, San Diego or Teknova, San Diego) was added and tubes were incubated at 37 °C, 200 rpm for 1 hour. 100 pL of culture was plated onto antibiotic selection plates (BioPioneer, San Diego or Teknova, San Diego), and incubated at 37 °C overnight.Docket No. LASS-009 / 01WO 338600-2154[000401] Plates were sent for colony sequencing of the antibody genes (Genewiz or Eton) where 24-48 clones per plate are sequenced. Sequences were analyzed with SnapGene Software (GSL Biotech) against the reference sequence which is an in silico cloning of the library. Clones were picked based on sequence alignment and amino acids that are encoded by the mutation primer, and used to generate individual plasmid mini-preps.[000402] Screening of mutants was achieved by small scale expression of the library derived plasmids in Expi293F cells cultured in 48-well plates using methodology described below. Heavy and light chain pairings were done in a 1 :2 ratio (0.5 ng HC: 1 ng LC plasmid per well). Replicates of the parental antibody control were included on each plate. Cells were grown in plates for 3 days, after which supernatant from each well was harvested for screening.[000403] Screening of plate transfections was done using biolayer interferometry (BLI). Initially, BLI was used to determine the concentration of antibody present in each sample, prior to screening for binding affinity to IL-11. Initial apparent binding kinetic measurements were taken on a Fortebio Octet RED96e instrument. mAbs were loaded onto anti-human constant domain (AHC) biosensors (ForteBio) in lOx kinetics buffer consisting of PBS, 0.1% BSA, 0.02% Tween 20 for 120 seconds to achieve a spectral shift value of 0.8 to 1.2 nm. The association phase was carried out in the presence of 20 nM of human, cyno, or murine IL-11 and was allowed to proceed for 120 s; dissociation was measured for 300 s to determine if any variants displayed improved on- or off- rates as compared to the parental antibody. Candidates presenting with apparent improved binding kinetics based on the single screening concentration were then retested for full binding kinetics vs each ortholog and recombined with other mutations as described below.HEK293 Cell Reporter Assay[000404] The STAT3 Reporter (Luciferase) - HEK293 cell line (BPS Bioscience, catalog #79800- P) was grown, passaged, and assayed as per manufacturer’s protocols. Cells were added at 25,000 cells per well in a 96-well microtiter dish and incubated at 37 °C for 30-45 min. in 5% CO2 humidified air. Anti-IL-11 mAbs were added as a 3-fold dilution series in duplicate columns or rows, and plates were returned to the incubator for an additional 1 h at 37 °C after which 40 ng / mL IL-11 was added to each well to initiate the signal transduction cascade and luciferase production. Plates were incubated for 18-24 hours at 37°C and luciferase was detected using a One-Step Luciferase Assay System (BPS Bioscience, cat. no. 60690-1) as per manufacturer’s instructions.Docket No. LASS-009 / 01WO 338600-2154 fHDF / TERT166 pSTAT3 assays[000405] The immortalized fHDF / TERT166 human foreskin fibroblast cell line was obtained from Evercyte GmbH (cat. no. CHT-031-0166-p) and then grown and passaged as recommended by the vendor. For the assay, cells were plated in full growth media (DMEM / F12 + glutamine / NaHCCh (ThermoFisher, cat. no. 1132033), 100 pg / mL G418 (InvivoGen, cat. no. ant-gn5), and 10% FBS (R&D Systems cat. no. SI 1150 / SHD)) at 5 x 103cells per well in a 96-well plate (Corning Costar 96-well tissue culture treated flat bottom plate (cat. no. 07-200-565)) and allowed to attach overnight. Media was then removed and switched directly into 100 pL of starvation media (i.e., growth media without FBS) for 18-24 hours.[000406] On the day of the assay, starvation media was replaced with 160 pL of fresh starvation media. After incubating for 60 min., 20 pL of lOx test article dilutions was added to each well of the 96-well plate. Assays were run using 10 different concentrations in half-log steps starting at 200 nM to generate an inhibition curve. After 60 min. of pre-incubation with test article, cells were stimulated with 30 ng / mL of IL-11 (Recombinant Human IL-11, ThermoFisher cat. no. PHC0115) or starvation media for vehicle control and incubated for 30 min. prior to lysis.[000407] Cells were prepared for staining by fixing with 100 pL of 4% NBF (neutral buffered formalin) and incubated at room temperature for 10 min. Cells were subsequently incubated for 10 min. at room temperature in 100 pL of 100 mM glycine pH7.2 and 100 pL of PBS + 0.1% Triton X-100 before decanting. Wells were washed 3x using 100 pL of PBS + 0.1% Tween 20 (PBST) and then blocked in 100 pL of blocking buffer (PBST with 1% BSA) for 1 hour.[000408] Following the preparation, a solution of anti-phosphoSTAT3 primary antibody (Phospho- ST AT2 (tyr 705) (D3A7) XP Rabbit mAb #9145, Cell Signaling cat. no. 9145L) was made in blocking buffer at a dilution factor of 1 : 100. 50 pL of this primary antibody solution was pipetted into each well and the plate was then sealed with Parafilm and incubated overnight at 4 °C.[000409] On the final day, plates were decanted and washed 3x using 100 pL of PBST per well. A secondary antibody cocktail was prepared in blocking buffer at 1 :250 dilution of donkey antirabbit IgG (H+L) highly cross-adsorbed secondary antibody Alexa Fluor 568 (ThermoFisher cat. no. A10042) and 1 :5000 Hoechst stain (Hoechst 3325, Pentahydrate (bis-benzamide) ThermoFisher cat. no. 1398). 50 pL of the secondary antibody cocktail was pipetted into each well and the entire plate was incubated at room temperature in the dark for 1 h. Following incubation, each well was washed 3x using 100 pL of PBST, and then 200 pL of PBS was pipetted into eachDocket No. LASS-009 / 01WO 338600-2154 well. The plate was then imaged on a Cytation 5 imaging multimode reader (Biotek) in the DAPI and Texas Red channels at lOx magnification. Images were pre-processed then analyzed for Object Mean in the Texas Red channel, gated to the nucleus.Results[000410] Cohorts of DiversimAb™ mice (Abveris Inc.) were immunized with human IL-11- mouse Fc fusion protein. Titers to purified human, cyno, and mouse recombinant IL-11 with his tags were measured by ELISA and mice with high titers were selected for preparation of hybridomas using established techniques. Hybridoma supernatants were tested for binding to human, cyno, and mouse recombinant IL-11 with his tags in initial screening and positive hits were further tested using biolayer interferometry (Octet analysis) to allow ranking of the antibodies by antigen binding affinity (KD) and whether or not they were potential IL- 11 neutralizing antibodies. Potential neutralization was tested by whether or not IL- 11 binding to soluble IL- 11 receptor alpha could take place in the presence of each test antibody. Antibodies that inhibited IL-11 receptor alpha binding were considered as potentially neutralizing. Results (Table 1) identified a panel of monoclonal antibodies from the hybridomas with preliminary binding affinities to IL- 11 of each species as well as categorization as potentially neutralizing or not.Table 1: IL-llRa neutralization by IL-11 specific monoclonal antibodiesDocket No. LASS-009 / 01WO 338600-2154

[0002] N.B. = no binding[000411] Clones of interest were used to isolate sequences from the antibody variable domains (Table 1), which were then used to construct chimeric antibodies with human IgGlK constant domains for further testing. Chimeric antibodies were tested for binding to human, cynomolgus monkey and mouse IL-11 by biolayer interferometry (Octet analysis) to determine binding affinity. Antibodies were also tested for bioactivity in a HEK293 cell-based reporter assay. IL-11 is reported to signal through the STAT3 and ERK pathways. Therefore, a STAT3 reporter cell line in which firefly luciferase gene expression is driven by STAT3 response elements located upstream of a minimal TATA promoter was selected to analyze mAb functional activity. In these cells, IL-11 can activate the endogenous STAT3 allowing it to bind to the STAT3 response elements, inducing transcription of the luciferase reporter gene and resulting in readily detectableDocket No. LASS-009 / 01WO 338600-2154 luciferase expression. Antibodies to IL-11 which block IL-11 signaling should inhibit expression of IL- 11 driven luciferase in these cells. Results from these analyses are shown in Table 2.Table 2: Binding of chimeric antibodies to human, cynomolgus monkey and mouse IL-11 measured by biolayer interferometry[000412] Two antibodies were selected for humanization and optimization, 3E11 and 11B6. Antibodies were expressed with either human IgGl or human IgG4 heavy chain constant regions and kappa light chain constant regions.[000413] To affinity mature the humanized antibodies, we prepared libraries of mAb variants centered on the HC and LC CDRs. To accomplish this, CDR amino acids were replaced in turn with up to 17 amino acid substitutions - cysteine and tryptophan were not included in the libraries so as to not introduce unwanted potential sequence liabilities, nor was the parental amino acid already in position included in the screen. Upon generation, the variants were first screened at a single concentration of human, and cyno IL-11 by BLI to determine if any had improved on- or off-rates as compared to the parental antibody. Screening identified a variety of single point variants that did indeed improve apparent binding kinetics. Individual mutations may be able toDocket No. LASS-009 / 01WO 338600-2154 be recombined to further improve binding affinity for the target antigen, though not in all cases.Humanization and Optimization of 3E11[000414] The heavy chain CDRs of 3E11 were grafted on to the human germline framework sequence IGHV 1-69-2 and the light chain to the human light chain germline sequence IGKV1-12 with back-mutations to the murine antibody derived amino acids at positions 48, 91 and 94 in the heavy chain numbered according to Kabat. A number of additional humanized versions of 3E11 were also produced as shown in Table 3. Analysis of IL-11 binding of the three variants by biolayer interferometry showed LT400 (also termed LA0063a) had the highest affinity for binding and therefore this was used for further maturation.[000415] Affinity maturation of LT400 carried out as described above resulted in discovery of a number of amino acid substitutions which improved the binding affinity and / or functional activity of the antibody. Functional activity was assessed for selected antibodies using the STAT3 reporter assay described above. These were recombined to identify recombined variants which were further improved. Table 3 describes single amino acid substitutions and recombined variants with improved properties.Table 3: Measured KD and IC50 of LT400 affinity matured clonesDocket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154nm = not measuredHumanization and Optimization of 11B6[000416] The CDRs of antibody 11B6 were grafted on to the human germline sequences IGHV1- 2 and IGKV4-1 with one back-mutation to the murine antibody derived sequence at position 39 in the light chain (Kabat numbering). Binding affinity of the humanized antibody (also termed LA0053a) for both human and cynomolgus monkey IL-11 was tested using biolayer interferometry on an Octet RED instrument. The results shown in Table 4 below indicated that humanized 11B6, termed LT600 or LA0053a, had similar, binding affinity for human and cynomolgus monkey IL-11, and was weaker for mouse IL-11. The kinetics values of Table 4 are listed as the average values of three independent experiments.Table 4: Affinity of humanized 11B6 (LA0053a) for human, cyno, and murine IL-11 orthologs.[000417] A number of additional humanized versions of 11B6 (LT600 or LA0053a) were also produced as shown in Table 5. Affinity maturation of LT600 (LA0053a) carried out as described above resulted in discovery of a number of amino acid substitutions which improved the binding affinity and / or functional activity of the antibody. These were recombined to identify recombined variants which were further improved. Table 5 describes single amino acid substitutions and recombined variants with improved properties.Table 5: Measured KD and IC50 of LT600 affinity matured clonesDocket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154Docket No. LASS-009 / 01WO 338600-2154

[0010] nm = not measured[000418] Three improving mutations, Y32N, S99A and SlOOcN were recombined to produceDocket No. LASS-009 / 01WO 338600-2154LA0060a. This antibody showed improved binding kinetics by BLI (octet) analysis with the KD value being below the limit of detection of the instrument. In addition, the functional potency of LA0060a was improved compared to LA0053a for inhibition of both human (FIG. 1A) and cynomolgus monkey (FIG. IB) IL-11 driven signaling. Further modifications to the sequence of LA0060a were made to remove any potentially problematic sequences that might give rise to pharmaceutical development liabilities. LA0054a included changes to remove a potential isomerization site in HC CDR3 (DG to EG), a DS motif in LC FW 1 (DS to SS), and an NG motif in HC CDR2. Binding affinity for LA0054a was again beyond the detection limit of the BLI technique, and functional potency further improved over that of LA0060a as shown in FIGs. 1A and IB. Tables 6A and 6B below provide IC50 data for LA0053a, LA0060a, and LA0054a with human (Table 6 A) and cynomolgus monkey (Table 6B) IL-11.Table 6A.Table 6B.[000419] To further test functional properties, the potency of LA0053a, LA0060a and LA0054a was tested in an assay to measure inhibition of human IL- 11 -mediated phosphorylation of STAT3 (pSTAT3) in a human dermal fibroblast cell line, fHDF / TERT166 cells as described in materials and methods section. Results shown in FIG. 2 demonstrate that the antibodies also have high potency at inhibiting IL-11 signaling in this fibroblast cell line which natively expresses IL-11 receptor, with LA0054a being the most potent of these three.Example 2: Effects of anti-IL-11 antibodies on TED patient derived fibroblasts[000420] To assess the role of IL-11 in thyroid eye disease, fibroblasts were isolated from orbital tissue of patients with thyroid eye disease (TED) and healthy donors. As shown in FIGs. 3A and 3B, IL- 11 and IL-l lRa mRNA levels were elevated in orbital fibroblasts from TED patientsDocket No. LASS-009 / 01WO 338600-2154(n=22) compared to healthy donor cells (n=8). TED orbital fibroblasts were then stimulated in culture with recombinant human IL-11 in the presence and absence of the IL-11 blocking antibody LA0054a. The production of excess hyaluronan (HA), a hydrophilic polymer, is pathologic in TED leading to tissue edema (Lee & Kahaly (2022) https: / / doi.Org / 10.1016 / j.beem.2022.101620). IL- 11 induced production of excess HA in TED patient-derived orbital fibroblasts. LA0054a inhibited HA release in a dose dependent manner (FIG. 4). The activity of LA0054a was tested on additional parameters relevant to thyroid eye disease including cell proliferation and production of inflammatory cytokines and chemokines.[000421] Orbital adipose / connective tissue was isolated from TED patients during orbital decompression surgery. Following isolation, tissues were minced into 1-2 mm pieces, placed in T75 culture dishes containing 15 mL of growth media (high glucose Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 20% fetal bovine serum and 1% penicillin / streptomycin; all from Gibco Laboratories, New York, USA), and incubated at 37 °C with 5% CO2. Culture medium was renewed every 3-4 days and tissue was maintained in culture for 2-3 weeks to allow the orbital fibroblasts to migrate out of the tissue.[000422] Following isolation, orbital fibroblasts (passage <5) were plated on black, clear flat bottom, 96-well plates (Corning Costar, catalog #3603) at 1 x 104cells / well (200 pL volume) for cell proliferation or on clear 6-well flat bottom plates (Gen Clone, cat #25-105) at 1 x 105cells / well (2 mL volume) for HA and procollagen release in growth media consisting of Dulbecco’s modified Eagle’s medium (DMEM) with high glucose GlutaMAX Supplement, pyruvate (Cat#10569010, Invitrogen, Life Technologies, Paisley, UK), supplemented with 20% fetal bovine serum (Cat# SI 1150, Lot B23041), R&D Systems), 100 lU / mL penicillin, and 100 g / mL streptomycin (Cat#15140122, Invitrogen), and incubated at 37°C with 5% CO2. The following day, media was changed to 100 pL (96 well plate) or 2 mL (6 well plate) of starvation media (growth media with 1% FBS) for 24 hr to synchronize cells. The following day, media was replaced with fresh serum-starvation media and cells were incubated with the conditions shown in each figure for an additional 96 hr. Following the 96 hr stimulation period, an aliquot of media was removed and frozen at -80OC for analysis of HA, IL-6 and MCP-1 / CCL2 release using the human HA (R&D Systems, catalog# DY3614), IL-6 (Cat#: DY206, R&D Systems) CCL2 / MCP- 1 (Cat#DY279, R&D Systems) DuoSet ELISA’ s according to manufacturer’s recommendations. Procollagen I was analyzed using the Human Pro-Collagen I alpha 1 ELISA Kit (Abeam; ab210966). To measure cell proliferation, WST-1 cell proliferation reagent (Sigma-Aldrich,Docket No. LASS-009 / 01WO 338600-2154 catalog# 11644807001) was added to each well, per manufacturers recommendations, and cell proliferation was assessed after a 2 hr incubation by measuring OD450 on a Spectramax iD5 plate reader (Molecular Devices, San Jose, CA.).[000423] As shown in FIGs. 5A-5D, LA0054a was able to inhibit multiple pathologic factors relevant to TED when orbital fibroblasts were stimulated with a combination of IL-11 and IGF-1, a growth factor reported to be important to the pathology of the disease. These factors include orbital fibroblast proliferation (FIG. 5A), production of HA (FIG. 5B), and production of IL-6 (FIG. 5C) and MCP-1 (CCL2, FIG. 5D). The infiltration of immune cells is a key pathogenic feature of TED and an area of ongoing therapeutic drug research. In particular, the upregulation of cytokines including IL-6 and MCP-1 / CCL2 is believed to promote activation of immune cells, including T cells, B cells, and orbital fibroblasts leading to orbital tissue expansion and remodeling (Fallahy et al., Front Endocrinol (Lausanne). 12:654473 (2021); Lee et al., Best Pract Res Clin Endocrinol Metab. 37(2): 101620 (2023); Zhang et al., J Immunol Res. 2528046 (2022)).[000424] LA0054a was also compared with a panel of IL-11 antibodies. These were ab89887, an anti-human IL-11 antibody from Abeam (Cambridge, UK), and two antibodies to IL-11 constructed from sequences in patent application WO2023 143556 Al, termed 8C8 and 18A10. These were produced with both human IgGl and human IgG4 constant regions. LA0054a was able to inhibit TED patient derived orbital fibroblast proliferation (FIG. 6A), production of HA (FIG. 6B), and production of IL-6 (FIG. 6C) and MCP-1 (CCL2, FIG. 6D) more efficiently than other antibodies tested.

Claims

1. Docket No. LASS-009 / 01WO 338600-2154CLAIMS1. An antibody specific for interleukin-11 (IL-11), wherein the antibody blocks or interferes with IL- 11 signaling, and wherein the antibody comprises a complementarity determining region (CDR) sequence combination of a.SEQ ID NOS: 657-662, wherein Xi = T, S, V, I, L, or D; X2= V, F, or I; X3= S, Y, A,H, V, G, S, F, N, P, or D; X4= A, G, S, L, or P; X5= V, P, T, L, S, A, G, Q, L, R, M, or H; X6= Q, V, T, D, R, A, S, or G; X7= E, K, R, V, M, or L; Xs = M, N, T, S, E, or R; X9= S, G, N, L, K, or I; Xio = F, H, N, or T; Xu = F, V, or A; X12 = L, V, or F; X13 = E, Q, T, or D; Xi4= R, F, S, N, G, H, I, L, V, Q, M, T, A, or Y; X15 = H, Y, V, S, F, D, E, T, A, M, or Q; Xi6= N, G, H, D, Y, K, Q, E, T, or S; Xi7= I, L, or F; and Xis = D, S, A, or P; or b. SEQ ID NOS: 665-670, wherein Xi = R, N, F, L, V, Y, H, M, K, A, E, or Q; X2 = Y, F, N, or H; X3= F, N, or H; X4= D or G; X5= V, I, or Y; X6= D; Xs = I or Y; X9= S; Xio = A, N or V; Xu = M or L; X12 = F or S; Xi3= S, F, H, or D; Xi4= T or K; X15 = L, R, or V; Xi6= Q, M, or N; X17 = I, F, H, G, V, Y, R, T, or A; Xis = Y or S; X19 = A; X20 = V, E, or M; X21 = F; X22 = N, V, or I; X23= R, Y, K, or A.

2. An antibody specific for interleukin- 11 (IL-11), wherein the blocks or interferes with IL-11 signaling, and wherein the antibody comprises: a.a heavy chain variable region (VH) comprising SEQ ID NO: 663; wherein Xi = T, S, V,I, L, or D; X2 = V, F, or I; X3= S, Y, A, H, V, G, S, F, N, P, or D; X4= A, G, S, L, or P; X5= V, P, T, L, S, A, G, Q, L, R, M, or H; X6= Q, V, T, D, R, A, S, or G; X7= E, K, R, V, M, or L; Xs = M, N, T, S, E, or R; X9= S, G, N, L, K, or I; Xio = F, H, N, or T; Xu = F, V, or A; X12 = L, V, or F; Xi3= E, Q, T, or D; Xi4= R, F, S, N, G, H, I, L, V, Q, M, T, A, or Y; and a light chain variable region (VL) comprising SEQ ID NO: 664; wherein X15 = H, Y, V, S, F, D, E, T, A, M, or Q; Xi6= N, G, H, D, Y, K, Q, E, T, or S; X17 = I, L, or F; and Xis = D, S, A, or P; or b. a VH comprising SEQ ID NO: 671; wherein Xi = R, N, F, L, V, Y, H, M, K, A, E, or Q; X2 = Y, F, N, or H; X3= F, N, or H; X4= D or G; X5= V, I, or Y; X6= D; X7 = R, K, E, M, T, A, or G; Xs = I or Y; X9= S; Xio= A, N or V; X11 = M or L; Xi2= F or S; Xi3= S, F, H, or D; Xi4= T or K; X15 = L, R, or V; Xi6= Q, M, or N; X17 = I, F, H, G,Docket No. LASS-009 / 01WO 338600-2154V, Y, R, T, or A; Xis = Y or S; X19 = A; X20 = V, E, or M; X21 = F; X22 = N, V, or I; X23 = R, Y, K, or A; and a VL comprising SEQ ID NO: 672; wherein X24= A, S, G, or L; X25 = T or F.

3. An antibody specific for interleukin- 11 (IL-11), wherein the antibody blocks or interferes with IL- 11 signaling, and wherein the antibody comprises a complementarity determining region (CDR) sequence combination selected from the group consisting of a.SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQID NO: 6; b. SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12;C. SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, and SEQ ID NO: 18; d. SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24; e.SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, and SEQ ID NO: 30; f. SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, and SEQ ID NO: 36; g.SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, and SEQ ID NO: 42; h. SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, and SEQ ID NO: 48; i. SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, and SEQ ID NO: 54; j. SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, and SEQ ID NO: 60; k. SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, and SEQ ID NO: 66; l. SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72; m. SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77,Docket No. LASS-009 / 01WO 338600-2154 and SEQ ID NO: 78; n. SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, and SEQ ID NO: 84; o.SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, and SEQ ID NO: 90; p. SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, and SEQ ID NO: 96; q. SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, and SEQ ID NO: 102; r.SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO:107, and SEQ ID NO: 108; s. SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO:113, and SEQ ID NO: 114; t. SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO:119, and SEQ ID NO: 120; u. SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, and SEQ ID NO: 126; v.SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO:131, and SEQ ID NO: 132; w. SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, and SEQ ID NO: 138; x.SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO:143, and SEQ ID NO: 144; y.SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO:149, and SEQ ID NO: 150; z. SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO:155, and SEQ ID NO: 156; aa. SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, and SEQ ID NO: 162; bb. SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, and SEQ ID NO: 168; cc. SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO:Docket No. LASS-009 / 01WO 338600-2154173, and SEQIDNO: 174; dd. SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178, SEQ ID NO: 179, and SEQIDNO: 180; ee. SEQIDNO: 181, SEQIDNO: 182, SEQIDNO: 183, SEQIDNO: 184, SEQIDNO: 185, and SEQIDNO: 186; ff. SEQIDNO: 187, SEQIDNO: 188, SEQIDNO: 189, SEQIDNO: 190, SEQIDNO: 191, and SEQIDNO: 192; gg. SEQ ID NO: 193, SEQ ID NO: 194, SEQ ID NO: 195, SEQ ID NO: 196, SEQ ID NO: 197, and SEQIDNO: 198; hh. SEQ ID NO: 199, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID NO: 202, SEQ ID NO: 203, and SEQ ID NO: 204; ii. SEQ ID NO: 205, SEQ ID NO: 206, SEQ ID NO: 207, SEQ ID NO: 208, SEQ ID NO: 209, and SEQIDNO: 210; jj. SEQ ID NO: 211, SEQ ID NO: 212, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215, and SEQIDNO: 216; kk. SEQIDNO: 217, SEQIDNO: 218, SEQIDNO: 219, SEQIDNO: 220, SEQIDNO: 221, and SEQIDNO: 222;11. SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, and SEQ ID NO: 228; mm. SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, and SEQ ID NO: 234; nn. SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, and SEQ ID NO: 240; oo. SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, and SEQ ID NO: 246; pp. SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, and SEQIDNO: 252; qq. SEQ ID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, and SEQ ID NO: 258; rr. SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, and SEQ ID NO: 264; ss. SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO:Docket No. LASS-009 / 01WO 338600-2154269, and SEQ ID NO: 270; tt. SEQ ID NO: 271, SEQ ID NO: 272, SEQ ID NO: 273, SEQ ID NO: 274, SEQ ID NO: 275, and SEQ ID NO: 276; uu. SEQ ID NO: 277, SEQ ID NO: 278, SEQ ID NO: 279, SEQ ID NO: 280, SEQ ID NO: 281, and SEQ ID NO: 282; vv. SEQ ID NO: 283, SEQ ID NO: 284, SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 287, and SEQ ID NO: 288; ww. SEQ ID NO: 289, SEQ ID NO: 290, SEQ ID NO: 291, SEQ ID NO: 292, SEQ ID NO: 293, and SEQ ID NO: 294; xx. SEQ ID NO: 295, SEQ ID NO: 296, SEQ ID NO: 297, SEQ ID NO: 298, SEQ ID NO: 299, and SEQ ID NO: 300; yy. SEQ ID NO: 301, SEQ ID NO: 302, SEQ ID NO: 303, SEQ ID NO: 304, SEQ ID NO: 305, and SEQ ID NO: 306; zz. SEQ ID NO: 307, SEQ ID NO: 308, SEQ ID NO: 309, SEQ ID NO: 310, SEQ ID NO: 311, and SEQ ID NO: 312; aaa. SEQ ID NO: 313, SEQ ID NO: 314, SEQ ID NO: 315, SEQ ID NO: 316, SEQ ID NO: 317, and SEQ ID NO: 318; bbb. SEQ ID NO: 319, SEQ ID NO: 320, SEQ ID NO: 321, SEQ ID NO: 322, SEQ ID NO: 323, and SEQ ID NO: 324; ccc. SEQ ID NO: 325, SEQ ID NO: 326, SEQ ID NO: 327, SEQ ID NO: 328, SEQ ID NO: 329, and SEQ ID NO: 330; ddd. SEQ ID NO: 331, SEQ ID NO: 332, SEQ ID NO: 333, SEQ ID NO: 334, SEQ ID NO: 335, and SEQ ID NO: 336; eee. SEQ ID NO: 337, SEQ ID NO: 338, SEQ ID NO: 339, SEQ ID NO: 340, SEQ ID NO: 341, and SEQ ID NO: 342; fff. SEQ ID NO: 343, SEQ ID NO: 344, SEQ ID NO: 345, SEQ ID NO: 346, SEQ ID NO: 347, and SEQ ID NO: 348; ggg. SEQ ID NO: 349, SEQ ID NO: 350, SEQ ID NO: 351, SEQ ID NO: 352, SEQ ID NO: 353, and SEQ ID NO: 354; hhh. SEQ ID NO: 355, SEQ ID NO: 356, SEQ ID NO: 357, SEQ ID NO: 358, SEQ ID NO: 359, and SEQ ID NO: 360; iii. SEQ ID NO: 361, SEQ ID NO: 362, SEQ ID NO: 363, SEQ ID NO: 364, SEQ ID NO:Docket No. LASS-009 / 01WO 338600-2154365, and SEQ ID NO: 366; jjj. SEQ ID NO: 367, SEQ ID NO: 368, SEQ ID NO: 369, SEQ ID NO: 370, SEQ ID NO: 371, and SEQ ID NO: 372; kkk. SEQ ID NO: 373, SEQ ID NO: 374, SEQ ID NO: 375, SEQ ID NO: 376, SEQ ID NO: 377, and SEQ ID NO: 378;111. SEQ ID NO: 379, SEQ ID NO: 380, SEQ ID NO: 381, SEQ ID NO: 382, SEQ ID NO: 383, and SEQ ID NO: 384; mmm. SEQ ID NO: 385, SEQ ID NO: 386, SEQ ID NO: 387, SEQ ID NO: 388, SEQ ID NO: 389, and SEQ ID NO: 390; nnn. SEQ ID NO: 391, SEQ ID NO: 392, SEQ ID NO: 393, SEQ ID NO: 394, SEQ ID NO: 395, and SEQ ID NO: 396;000. SEQ ID NO: 397, SEQ ID NO: 398, SEQ ID NO: 399, SEQ ID NO: 400, SEQ ID NO: 401, and SEQ ID NO: 402; ppp. SEQ ID NO: 403, SEQ ID NO: 404, SEQ ID NO: 405, SEQ ID NO: 406, SEQ ID NO: 407, and SEQ ID NO: 408; qqq. SEQ ID NO: 409, SEQ ID NO: 410, SEQ ID NO: 411, SEQ ID NO: 412, SEQ ID NO: 413, and SEQ ID NO: 414; rrr. SEQ ID NO: 415, SEQ ID NO: 416, SEQ ID NO: 417, SEQ ID NO: 418, SEQ ID NO: 419, and SEQ ID NO: 420; sss.SEQ ID NO: 421, SEQ ID NO: 422, SEQ ID NO: 423, SEQ ID NO: 424, SEQ ID NO: 425, and SEQ ID NO: 426; ttt. SEQ ID NO: 427, SEQ ID NO: 428, SEQ ID NO: 429, SEQ ID NO: 430, SEQ ID NO: 431, and SEQ ID NO: 432; uuu. SEQ ID NO: 433, SEQ ID NO: 434, SEQ ID NO: 435, SEQ ID NO: 436, SEQ ID NO: 437, and SEQ ID NO: 438; vvv. SEQ ID NO: 439, SEQ ID NO: 440, SEQ ID NO: 441, SEQ ID NO: 442, SEQ ID NO: 443, and SEQ ID NO: 444;WWW. SEQ ID NO: 445, SEQ ID NO: 446, SEQ ID NO: 447, SEQ ID NO: 448, SEQ ID NO: 449, and SEQ ID NO: 450; xxx. SEQ ID NO: 451, SEQ ID NO: 452, SEQ ID NO: 453, SEQ ID NO: 454, SEQ ID NO: 455, and SEQ ID NO: 456; yyy. SEQ ID NO: 457, SEQ ID NO: 458, SEQ ID NO: 459, SEQ ID NO: 460, SEQ IDDocket No. LASS-009 / 01WO 338600-2154NO: 461, and SEQ ID NO: 462; zzz. SEQ ID NO: 463, SEQ ID NO: 464, SEQ ID NO: 465, SEQ ID NO: 466, SEQ ID NO: 467, and SEQ ID NO: 468; aaaa. SEQ ID NO: 469, SEQ ID NO: 470, SEQ ID NO: 471, SEQ ID NO: 472, SEQ ID NO: 473, and SEQ ID NO: 474; bbbb. SEQ ID NO: 475, SEQ ID NO: 476, SEQ ID NO: 477, SEQ ID NO: 478, SEQ ID NO: 479, and SEQ ID NO: 480; cccc. SEQ ID NO: 481, SEQ ID NO: 482, SEQ ID NO: 483, SEQ ID NO: 484, SEQ ID NO: 485, and SEQ ID NO: 486; and dddd. SEQ ID NO: 487, SEQ ID NO: 488, SEQ ID NO: 489, SEQ ID NO: 490, SEQ ID NO: 491, and SEQ ID NO: 492.

4. An antibody specific for interleukin- 11 (IL-11), wherein the antibody blocks or interferes with IL-11 signaling, and wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: a.the VH comprises a sequence according to SEQ ID NO: 493 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 494 or a sequence at least 70% identical thereto; b. the VH comprises a sequence according to SEQ ID NO: 495 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 496 or a sequence at least 70% identical thereto; c.the VH comprises a sequence according to SEQ ID NO: 497 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 498 or a sequence at least 70% identical thereto; d. the VH comprises a sequence according to SEQ ID NO: 499 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 500 or a sequence at least 70% identical thereto; e.the VH comprises a sequence according to SEQ ID NO: 501 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 502 or a sequence at least 70% identical thereto; f. the VH comprises a sequence according to SEQ ID NO: 503 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 504 or a sequence at least 70% identical thereto;Docket No. LASS-009 / 01WO 338600-2154 g.the VH comprises a sequence according to SEQ ID NO: 505 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 506 or a sequence at least 70% identical thereto; h. the VH comprises a sequence according to SEQ ID NO: 507 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 508 or a sequence at least 70% identical thereto; i. the VH comprises a sequence according to SEQ ID NO: 509 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 510 or a sequence at least 70% identical thereto; j. the VH comprises a sequence according to SEQ ID NO: 511 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 512 or a sequence at least 70% identical thereto; k. the VH comprises a sequence according to SEQ ID NO: 513 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 514 or a sequence at least 70% identical thereto; l. the VH comprises a sequence according to SEQ ID NO: 515 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 516 or a sequence at least 70% identical thereto; m. the VH comprises a sequence according to SEQ ID NO: 517 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 518 or a sequence at least 70% identical thereto; n. the VH comprises a sequence according to SEQ ID NO: 519 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 520 or a sequence at least 70% identical thereto; o.the VH comprises a sequence according to SEQ ID NO: 521 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 522 or a sequence at least 70% identical thereto; p. the VH comprises a sequence according to SEQ ID NO: 523 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 524 or a sequence at least 70% identical thereto; q. the VH comprises a sequence according to SEQ ID NO: 525 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 526 or aDocket No. LASS-009 / 01WO 338600-2154 sequence at least 70% identical thereto; r.the VH comprises a sequence according to SEQ ID NO: 527 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 528 or a sequence at least 70% identical thereto; s.the VH comprises a sequence according to SEQ ID NO: 529 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 530 or a sequence at least 70% identical thereto; t. the VH comprises a sequence according to SEQ ID NO: 531 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 532 or a sequence at least 70% identical thereto; u. the VH comprises a sequence according to SEQ ID NO: 533 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 534 or a sequence at least 70% identical thereto; v.the VH comprises a sequence according to SEQ ID NO: 535 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 536 or a sequence at least 70% identical thereto; w. the VH comprises a sequence according to SEQ ID NO: 537 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 538 or a sequence at least 70% identical thereto; x.the VH comprises a sequence according to SEQ ID NO: 539 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 540 or a sequence at least 70% identical thereto; y.the VH comprises a sequence according to SEQ ID NO: 541 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 542 or a sequence at least 70% identical thereto; z.the VH comprises a sequence according to SEQ ID NO: 543 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 544 or a sequence at least 70% identical thereto; aa. the VH comprises a sequence according to SEQ ID NO: 545 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 546 or a sequence at least 70% identical thereto; bb.the VH comprises a sequence according to SEQ ID NO: 547 or a sequence at least 70%Docket No. LASS-009 / 01WO 338600-2154 identical thereto, and the VL comprises a sequence according to SEQ ID NO: 548 or a sequence at least 70% identical thereto; cc. the VH comprises a sequence according to SEQ ID NO: 549 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 550 or a sequence at least 70% identical thereto; dd.the VH comprises a sequence according to SEQ ID NO: 551 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 552 or a sequence at least 70% identical thereto; ee. the VH comprises a sequence according to SEQ ID NO: 553 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 554 or a sequence at least 70% identical thereto; ff. the VH comprises a sequence according to SEQ ID NO: 555 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 556 or a sequence at least 70% identical thereto; gg. the VH comprises a sequence according to SEQ ID NO: 557 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 558 or a sequence at least 70% identical thereto; hh.the VH comprises a sequence according to SEQ ID NO: 559 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 560 or a sequence at least 70% identical thereto; ii. the VH comprises a sequence according to SEQ ID NO: 561 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 562 or a sequence at least 70% identical thereto; jj. the VH comprises a sequence according to SEQ ID NO: 563 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 564 or a sequence at least 70% identical thereto; kk.the VH comprises a sequence according to SEQ ID NO: 565 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 566 or a sequence at least 70% identical thereto;11. the VH comprises a sequence according to SEQ ID NO: 567 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 568 or a sequence at least 70% identical thereto;Docket No. LASS-009 / 01WO 338600-2154 mm. the VH comprises a sequence according to SEQ ID NO: 569 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 570 or a sequence at least 70% identical thereto; nn.the VH comprises a sequence according to SEQ ID NO: 571 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 572 or a sequence at least 70% identical thereto; oo. the VH comprises a sequence according to SEQ ID NO: 573 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 574 or a sequence at least 70% identical thereto; pp.the VH comprises a sequence according to SEQ ID NO: 575 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 576 or a sequence at least 70% identical thereto; qq.the VH comprises a sequence according to SEQ ID NO: 577 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 578 or a sequence at least 70% identical thereto; rr. the VH comprises a sequence according to SEQ ID NO: 579 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 580 or a sequence at least 70% identical thereto; ss. the VH comprises a sequence according to SEQ ID NO: 581 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 582 or a sequence at least 70% identical thereto; tt. the VH comprises a sequence according to SEQ ID NO: 583 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 584 or a sequence at least 70% identical thereto; uu.the VH comprises a sequence according to SEQ ID NO: 585 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 586 or a sequence at least 70% identical thereto; vv. the VH comprises a sequence according to SEQ ID NO: 587 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 588 or a sequence at least 70% identical thereto; ww. the VH comprises a sequence according to SEQ ID NO: 589 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 590Docket No. LASS-009 / 01WO 338600-2154 or a sequence at least 70% identical thereto; xx. the VH comprises a sequence according to SEQ ID NO: 591 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 592 or a sequence at least 70% identical thereto; yy. the VH comprises a sequence according to SEQ ID NO: 593 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 594 or a sequence at least 70% identical thereto; zz. the VH comprises a sequence according to SEQ ID NO: 595 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 596 or a sequence at least 70% identical thereto; aaa. the VH comprises a sequence according to SEQ ID NO: 597 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 598 or a sequence at least 70% identical thereto; bbb. the VH comprises a sequence according to SEQ ID NO: 599 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 600 or a sequence at least 70% identical thereto; ccc. the VH comprises a sequence according to SEQ ID NO: 601 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 602 or a sequence at least 70% identical thereto; ddd. the VH comprises a sequence according to SEQ ID NO: 603 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 604 or a sequence at least 70% identical thereto; eee. the VH comprises a sequence according to SEQ ID NO: 605 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 606 or a sequence at least 70% identical thereto; fff. the VH comprises a sequence according to SEQ ID NO: 607 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 608 or a sequence at least 70% identical thereto; ggg. the VH comprises a sequence according to SEQ ID NO: 609 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 610 or a sequence at least 70% identical thereto; hhh. the VH comprises a sequence according to SEQ ID NO: 611 or a sequence at leastDocket No. LASS-009 / 01WO 338600-215470% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 612 or a sequence at least 70% identical thereto; iii. the VH comprises a sequence according to SEQ ID NO: 613 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 614 or a sequence at least 70% identical thereto; jjj. the VH comprises a sequence according to SEQ ID NO: 615 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 616 or a sequence at least 70% identical thereto; kkk. the VH comprises a sequence according to SEQ ID NO: 617 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 618 or a sequence at least 70% identical thereto;111. the VH comprises a sequence according to SEQ ID NO: 619 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 620 or a sequence at least 70% identical thereto; mmm. the VH comprises a sequence according to SEQ ID NO: 621 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 622 or a sequence at least 70% identical thereto; nnn. the VH comprises a sequence according to SEQ ID NO: 623 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 624 or a sequence at least 70% identical thereto; ooo. the VH comprises a sequence according to SEQ ID NO: 625 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 626 or a sequence at least 70% identical thereto; ppp. the VH comprises a sequence according to SEQ ID NO: 627 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 628 or a sequence at least 70% identical thereto; qqq. the VH comprises a sequence according to SEQ ID NO: 629 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 630 or a sequence at least 70% identical thereto; rrr. the VH comprises a sequence according to SEQ ID NO: 631 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 632 or a sequence at least 70% identical thereto;Docket No. LASS-009 / 01WO 338600-2154 sss.the VH comprises a sequence according to SEQ ID NO: 633 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 634 or a sequence at least 70% identical thereto; ttt. the VH comprises a sequence according to SEQ ID NO: 635 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 636 or a sequence at least 70% identical thereto; uuu. the VH comprises a sequence according to SEQ ID NO: 637 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 638 or a sequence at least 70% identical thereto; vw. the VH comprises a sequence according to SEQ ID NO: 639 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 640 or a sequence at least 70% identical thereto; www. the VH comprises a sequence according to SEQ ID NO: 641 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 642 or a sequence at least 70% identical thereto; xxx. the VH comprises a sequence according to SEQ ID NO: 643 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 644 or a sequence at least 70% identical thereto; yyy. the VH comprises a sequence according to SEQ ID NO: 645 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 646 or a sequence at least 70% identical thereto; zzz. the VH comprises a sequence according to SEQ ID NO: 647 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 648 or a sequence at least 70% identical thereto; aaaa. the VH comprises a sequence according to SEQ ID NO: 649 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 650 or a sequence at least 70% identical thereto; bbbb. the VH comprises a sequence according to SEQ ID NO: 651 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 652 or a sequence at least 70% identical thereto; cccc. the VH comprises a sequence according to SEQ ID NO: 653 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 654Docket No. LASS-009 / 01WO 338600-2154 or a sequence at least 70% identical thereto; or dddd. the VH comprises a sequence according to SEQ ID NO: 655 or a sequence at least 70% identical thereto, and the VL comprises a sequence according to SEQ ID NO: 656 or a sequence at least 70% identical thereto.

5. The antibody of any one of claims 1-4, wherein the antibody is a monoclonal antibody.

6. The antibody of any one of claims 1-4, wherein the antibody is an antibody fragment.

7. The antibody of any one of claims 1-4, wherein the antibody is a human antibody.

8. The antibody of any one of claims 1-4, wherein the antibody is a humanized antibody.

9. The antibody of any one of claims 1-4, wherein the antibody is a chimeric antibody.

10. The antibody of any one of claims 1-9, wherein the antibody comprises an Fc domain.

11. The antibody of claim 10, wherein the Fc domain is IgA (including subclasses IgAl and IgA2), IgD, IgE, IgG (including subclasses IgGl, IgG2, IgG3, and IgG4), or IgM Fc domain, optionally a human Fc domain, or a hybrid and / or variant thereof.

12. A pharmaceutical composition comprising the antibody of any one of claims 1-11, and a pharmaceutically-acceptable carrier.

13. A nucleic acid encoding the antibody of any one of claims 1-11.

14. A vector comprising the nucleic acid of claim 13.

15. A method of treating a disease or condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody of any one of claims 1-11 or the pharmaceutical composition of claim 12.

16. The method of claim 15, wherein the disease or condition is an IL- 11 -associated or IL-11- mediated disease or condition.

17. The method of claim 15, wherein the disease or condition is a cancer, an inflammatory disease, an autoimmune disease, a wasting disease, a bone disease, an age-related disease or disorder, or a fibro-inflammatory disease.

18. The method of claim 17, wherein the disease is a cancer, optionally a cancer that expresses or overexpresses IL-1 IRa and / or IL-11, optionally wherein the cancer displays IL-1 IRa / IL-l 1- dependent growth, adhesion, migration, invasion, and / or chemoresistance.

19. The method of claim 17 or 18, wherein the cancer is selected from one or more of bone cancer, prostate cancer, melanoma (e.g., metastatic melanoma), pancreatic cancer, small cell lung cancer, non-small cell lung cancer (NSCLC), mesothelioma, leukemia (e.g., lymphocytic leukemia, chronic myelogenous leukemia, acute myeloid leukemia, relapsed acute myeloidDocket No. LASS-009 / 01WO 338600-2154 leukemia, hairy cell leukemias, acute lymphoblastic leukemias), lymphoma (e.g., nonHodgkin’s lymphomas, Hodgkin’s lymphoma), hepatoma (hepatocellular carcinoma), sarcoma, B-cell malignancy, breast cancer, ovarian cancer, colorectal cancer, glioma, glioblastoma multiforme, meningioma, pituitary adenoma, vestibular schwannoma, primary CNS lymphoma, primitive neuroectodermal tumor (medulloblastoma), kidney cancer (e.g., renal cell carcinoma), bladder cancer, uterine cancer, esophageal cancer, brain cancer, head and neck cancers, cervical cancer, testicular cancer, thyroid cancer, and stomach cancer.

20. The method of any one of claims 17-19, wherein the cancer is a metastatic cancer, optionally a metastatic cancer which has metastasized to the bone.

21. The method of claim 17, wherein the inflammatory disease is selected from one or more of airway or lung inflammation (e.g., inflammatory lung disease), asthma, rhinitis, chronic obstructive pulmonary disorder (COPD), dermatitis, psoriasis, hepatitis, gastric inflammation, irritable bowel syndrome (IBS), ulcerative colitis, Crohn’s disease, colitis, diverticulitis, lupus erythematous, nephritis, Parkinson’s disease, multiple sclerosis (MS), Alzheimer’s disease, arthritis, rheumatoid arthritis, sepsis, infection-induced inflammation, cardiovascular diseases such as atherosclerosis and vasculitis, diabetes, and gout.

22. The method of claim 17, wherein the autoimmune disease is selected from one or more of arthritis (including rheumatoid arthritis, reactive arthritis), systemic lupus erythematosus (SLE), psoriasis, inflammatory bowel disease (IBD), ulcerative colitis, Crohn’s disease, encephalomyelitis, uveitis, myasthenia gravis, multiple sclerosis, insulin dependent diabetes, Addison’s disease, celiac disease, chronic fatigue syndrome, autoimmune hepatitis, autoimmune alopecia, ankylosing spondylitis, fibromyalgia, pemphigus vulgaris, Sjogren’s syndrome, Kawasaki’s Disease, hyperthyroidism / Graves’ disease, hypothyroidism / Hashimoto’s disease, endometriosis, scleroderma, pernicious anemia, Goodpasture syndrome, Guillain-Barre syndrome, Wegener’s disease, glomerulonephritis, aplastic anemia (including multiply transfused aplastic anemia patients), paroxysmal nocturnal hemoglobinuria, myelodysplastic syndrome, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, Evan’s syndrome, Factor VIII inhibitor syndrome, systemic vasculitis, dermatomyositis, polymyositis, rheumatic fever, autoimmune lymphoproliferative syndrome (ALPS), autoimmune bullous pemphigoid, Parkinson’s disease, sarcoidosis, vitiligo, primary biliary cirrhosis, and autoimmune myocarditis.

23. The method of claim 17, wherein the wasting disease is selected from one or more of cachexia,Docket No. LASS-009 / 01WO 338600-2154 optionally cachexia associated with cancer or renal failure, and sarcopenia.

24. The method of claim 17, wherein the bone disease is selected from osteoporosis (including post-menopausal osteoporosis), bone fracture, Paget’s disease of bone, and bone resorption / damage associated with cancer or cancer therapy, including chemotherapy, hormone ablation, and hormone inhibition.

25. The method of claim 17, wherein the fibro-inflammatory disease comprises fibrosis of the lungs, cardiovascular system, liver, brain, joints (optionally knee, hip, ankle, foot joints, shoulder, elbow, wrist, hand joints, or spinal vertebrae), intestine, skin, kidney, liver, thyroid, bone marrow, retroperitoneum, or eye.

26. The method of claim 17 or 25, wherein the fibro-inflammatory disease is selected from the group consisting of fibrothorax, pulmonary fibrosis (optionally cystic fibrosis or interstitial lung disease (ILD)), autosomal recessive genetic disease optionally Hermansky-Pudlak syndrome, radiation-induced lung injury, myocardial fibrosis (optionally interstitial fibrosis or replacement fibrosis) and thyroid eye disease (TED).

27. The method of claim 26, wherein the ILD is idiopathic ILD, optionally selected from idiopathic pulmonary fibrosis (IPF), desquamative interstitial pneumonia (DIP), acute interstitial pneumonia (AIP) or Hamman-Rich syndrome, nonspecific interstitial pneumonia (NSIP), respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), cryptogenic organizing pneumonia (COP), and lymphoid interstitial pneumonia (LIP).

28. The method of claim 26, wherein the ILD is secondary ILD, optionally selected from ILD related to connective tissue and autoimmune diseases (optionally sarcoidosis, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, polymyositis, dermatomyositis, or anti synthetase syndrome), inhaled substances (optionally silicosis, asbestosis, berylliosis, industrial printing chemicals, or chronic hypersensitivity pneumonitis), drugs (optionally antibiotics, chemotherapeutics, or anti-arrhythmic agents), infections (optionally SARS CoV- 2, atypical pneumonia, pneumocystis pneumonia, tuberculosis, Chlamydia trachomatis, or respiratory syncytial virus), malignancies (optionally lymphangitic carcinomatosis), and pediatric ILDs (optionally developmental disorders, growth abnormalities deficient alveolarization, infant conditions of undefined cause, and ILD related to alveolar surfactant region).

29. The method of claim 17, wherein the age related disease or disorder is selected from the group consisting of cardiovascular disease (optionally atherosclerosis, hypertension, heart failure,Docket No. LASS-009 / 01WO 338600-2154 coronary artery disease), musculoskeletal disorders (optionally osteoarthritis, osteoporosis, sarcopenia), neurodegenerative disease (optionally Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s disease), metabolic disorders (optionally type 2 diabetes mellitus, metabolic syndrome, dyslipidemia, non-alcoholic fatty liver disease (NAFLD)), ophthalmological disorders, (optionally age-related macular degeneration (AMD), cataracts, glaucoma), pulmonary disorders (optionally chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF)), hematologic disorders (optionally anemia of aging, myelodysplastic syndromes), renal disorders (optionally chronic kidney disease, age- related nephrosclerosis), immune disorders (optionally immunosenescence, chronic inflammation), skin and connective tissue disorders (optionally wrinkles, skin thinning, photoaging, age-related fibrosis), cancer (optionally breast cancer, prostate cancer, colorectal cancer), and endocrine disorders (optionally hypogonadism, age-related hormone decline).

30. A method of preventing, ameliorating, or reversing cellular aging or senescence in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody of any one of claims 1-11 or the pharmaceutical composition of claim 12.

31. A method of inhibiting one or more of hyaluronan production, IL-6 production, and MCP-1 production by a cell, comprising contacting the cell with the antibody of any one of claims 1- 11 or the pharmaceutical composition of claim 12.

32. A method of inhibiting one or more of hyaluronan production, IL-6 production, and MCP-1 production in a subject, comprising administering to the subject a therapeutically effective amount of the antibody of any one of claims 1-11 or the pharmaceutical composition of claim 12.

33. A composition comprising the antibody of any one of claims 1-11 or the pharmaceutical composition of claim 12, for use in the treatment of a disease or condition.

34. The composition for use of claim 33, wherein the disease or condition is a cancer, an inflammatory disease, an autoimmune disease, a wasting disease, a bone disease, an age- related disease or disorder, or a fibro-inflammatory disease.

Images